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ABSTRACT
In the fight against disease and illness, nature has provided mankind some of our
best therapeutics in the form of secondary metabolites. The plant, fungi and animal
phyla inhabiting the Earth produce diverse and unique chemistry that can be used in our
fight against disease. In the growing threat of drug resistance and pathogen evolution,
the field of natural products chemistry strives to explore new biological and chemical
diversity sources, and develop innovative methodology to identify and isolate new
chemistry faster than ever.
The dissertation herein presented is one such effort to find new, bioactive
chemistry from the marine environments. New biodiversity sources, from the tropical
Floridian mangrove forests to the cold waters of the Antarctic oceans, were evaluated
for the new, unique chemistry they produce. A large-scale screening of epigenetically
modulated mangrove fungi was undertaken, producing a large, biologically and
chemically diverse extract library. New methodology was developed in order to evaluate
these extracts, leading to rapid identification and isolation of known and new bioactive
metabolites. From the Southern Oceans, a collection of sponges was studied, and a
new, highly unique peptide was isolated and characterized. These efforts were
undertaken in the continued effort to isolate new, unique lead compounds.

xiv

CHAPTER ONE:
NATURAL PRODUCTS AND DRUG DISCOVERY

1.1.

History of Natural Products
1.1.1. Natural Products in Antiquity
Before the dawn of modern anatomy, medicine, and chemistry, mankind’s grasp

of health and illness was ruled by the doctrine of humorism. Posited first by
Hippocrates, humorism viewed all humans as possessing temperaments linked to four
internal humors: the sanguine blood, aggressive yellow bile, melancholic black bile, and
peaceful phlegm. The rules of humorism were simple: when all four humors were in
balance, one was well and healthy; when they were corrupted, one became ill. 1
Unfortunately for mankind, but fortunately for legions of natural product chemists, the
interaction between humans and their illnesses is far more complex and enduring.
While early civilizations’ understanding of diseases may have been flawed,
treatment of illness using plants and herbs was consistent and widespread. Some of the
earliest documentation of plant-based medicine is from Ancient Mesopotamia, where
oils from Cedarus sp. (cedar) and Cupressus sempevirens (cypress) trees were used to
treat coughs and infections; extract from Papaver somniferum (poppy juice) (Figure
1.1.) is now famous for its use as an anti-infective and powerful painkiller.2 In ancient
Egypt, pomegranates and date palms were used as antiseptic agents, and to relieve
1

constipation. Honey was a staple in medicinal practices, used for its anti-infective
properties, and for preparation and delivery of oral and superficial medicines. 3 The
Chinese Materia Medica, the most extensive and enduring ancient medicinal
encyclopedia, records hundreds of herbal and plant remedies, the most well-known of
which is the use of ginseng (Panax sp.) by the wealthy classes for increased
intelligence and mental capability.2,4 In the Americas, Californian Indian tribes used
steeped bark and leaves of Artemisia californica (American Sagebrush) in alcohol to
create a powerful painkiller often used during labor and for serious wounds. 5

Figure 1.1. Seed capsule of Papavar somniferum, from which opium is derived.6

While these ancient cultures certainly understood the usefulness of these natural
remedies, the mechanisms by which they worked was elusive to them. Magic and
religious rituals were frequently incorporated in tandem with these medicines, and this
interaction was often credited for convalescence.2–5 But it wasn’t the ritual factors that
gave these extracts their medicinal properties; the properties of these plants and herbs
are a result of the metabolites that they produce, and that are extracted to make
medicine. It is not the poppy seed itself that acted as a painkiller and antibiotic. It is
2

morphine and codeine, the most prevalent alkaloids present in crude poppy extracts, 2
that are responsible, by binding to selective receptors throughout the central nervous
system and suppressing their behavior.7–10 The chemical nature of these medicines is
true of all ancient remedies. Cedar oil is a powerful antibiotic and antifungal agent due
to the synergistic role of anethole and taxifolin found in plant resin. 11–13 Ginseng
contains high concentrations of ginsenosides like Rb14 which can help increase the
uptake and release of choline and acetylcholine in the brain, which boosts brain
development and nerve growth.14–16 The American Sagebrush is useful as a painkiller
because of the high content of camphor and eucalyptol present in the alcoholic extracts
of the plants (Figure 1.2.).5,17
1.1.2. The Nature of Secondary Metabolites
The chemical constituents of plants and microorganisms maintain important roles
in society and medicine, and are among the earliest examples of natural products being
utilized to treat diseases and ailments. Their metabolic origins are critical in
understanding their role and adapting similar compounds to fight disease. Within all
living organisms, vast numbers of chemical compounds are taken in and interconverted
to allow an organism to grow and survive. The metabolic pathways responsible for this
produce primary metabolites, such as fats, sugars, proteins, and nucleic acids, which
are ubiquitous and essential for all life. However, there exists secondary metabolic
pathways, producing compounds with a much more limited distribution in nature. These
secondary metabolites, coined “natural products”, are often unessential to the growth
and survival of an organism, but they can play instrumental roles in its productivity and
fitness.18

3

Morphine

Codeine

Anethole

Taxifol

Ginsenoside Rb

Eucalyptol

Figure 1.2. Chemical structures of early, plant-derived natural products used therapeutically.

Secondary metabolites can perform a variety of functions in nature, ranging from
defensive functions to cell signaling and nutrient uptake. Defense of the organism is an
easily appreciated role of secondary metabolism. Many organisms, particularly sessile
plants and microorganisms, employ chemical defense to deter predators and to combat
competition. One of the most clinically relevant examples is the aflatoxin class of
mycotoxins produced by various species of fungi, including Aspergillus sp. Aflatoxins
are highly carcinogenic in mammals, and the metabolic derivatives can accumulate in
tissues, eggs, and milk. Production of such a toxic chemical can deter animal predators
from consuming the fungi in nature.19,20 Similarly, microorganisms employ chemical
defenses against other microorganisms. Penicillium spp. are famous for the production
of antibiotic penicillin-like compounds, providing a key defense for the fungi against
bacterial competitors (Figure 1.3.).

4

Figure 1.3. Secondary metabolites can play vital biological roles. (A) Fungi can produce
secondary metabolites with antibiotic properties. Photo by Janice Haney Carr, CDC Public Health
Image Library. (B) Bacteria can use secondary metabolites to signal the formation of biofilms.
Copyright © George Barron, University of Guelph, https://atrium.lib.uoguelph.ca , 2013

Secondary metabolites can also play vital roles in the uptake of scare nutrients required
for growth. Many fungi and bacteria produce siderophores, a class of small, ironchelating ligands that can be used to scavenge iron from an otherwise nutrient-poor
environment. The production of siderophores can greatly increase the absorption and
utilization of iron within microorganisms.21,22 Secondary metabolites can also serve to
signal between different organisms of the same species (pheromones) or to signal
directly or indirectly to organisms of different species (simiochemicals).23 Pheromones
are chemically and functionally diverse: many insects and mammals use volatile
chemicals to attract mates,23,24 while plants utilize biologically inactive compounds that,
in the presence of predator metabolites, react to form volatile pheromones to warn
neighboring organisms of predation,23 and bacteria utilize polypetide pheromones to
initiate community-wide activity, including biofilm formation and sporulation.

25

These

are just a few examples of the many functionally diverse, and often species-specific,
metabolites that, though unessential for survival, serve vital roles in the success of the
producing organism.

5

1.1.3. The Origin of Secondary Metabolism
There have been a number of historical theories to explain the origin of
secondary metabolism. Some theories viewed secondary metabolism as simply
“evolution in progress”,26 and that genes encoding for these metabolic pathways are
persistent, random mutations, or that the secondary metabolism functions as a chemical
source for potential future use by the organism, much like the mammalian immune
system.27 These models hold some merit, as most secondary metabolites have no
discernable purpose or function in the organism unless there is a specific external
stimulus. Other theories posit that secondary metabolism is only important in how it
supports primary metabolism, and specifically that secondary metabolites are
degradation products of primary metabolism, or that they were primary metabolites at
some point during the compounds existence in the cell.28 Some secondary metabolites
are derived from primary metabolites or primary metabolic pathways: some
siderophores like rhodotorluic acid, are derivatives of primary metabolites like citric
acid,21 and many insect pheromones are degradation productions of plant alkaloids
(Figure 1.4.).23 However, despite the examples supporting many of these theories, most
oversimplify the presence and genetic origin of secondary metabolism. The genes that
encode many secondary metabolites are now known to be consistent throughout many
generations of a species, and the genes are far too complex to be considered normal
mutations. The biosynthetic machinery utilized to create secondary metabolites are also
complex, and in many cases are energetically expensive. Considering the efficiency
with which primary metabolism occurs, and how its waste and detoxification products
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are eliminated, it seems unlikely that the advanced secondary metabolic processes
exist to assist primary metabolism or utilize excess primary metabolites.28

Monocrotalin
(Crotalaria spectabilis)

(R)-hydroxydanaidal
(Male pheromone of
Utetheisa ornatrix)

Figure 1.4. Outline of biosynthesis of Utetheisa ornatrix pheromone (R)-hydroxydanaidal from
plant-host obtained alkaloid monocrotaline.23

The most widely accepted, unifying model explains secondary metabolism as a
measure of fitness.28 When resources are plentiful enough to allow primary metabolism
to be maintained, secondary metabolism allows the organism to thrive, by aiding in
resource uptake, communication, and to attract or repel other organisms. This model
unifies the myriad forms and functions of secondary metabolites: siderophores are
derived from primary metabolites to aid in uptake of scarce nutrients, 21,22 pheromones
are used to attract mates,23,24 and toxins and defensive chemicals aid the organism in
competing for space and resources11,13,20,25. This model supports the complex genes
and biosynthetic pathways of secondary metabolism, as well as their persistence
through generations of a species. It has therefore been largely accepted that secondary
metabolites serve a role in the fitness of organisms, and that their necessity depends on
the environmental conditions of the organism, with resource abundance and fierce
competition inciting the production of unique, bioactive secondary metabolites.
7

1.2.

Natural Products as Therapeutics
1.2.1. Ancient Plant Remedies in the Modern World
The development of the modern pharmaceutical industry owes much to the

herbal remedies that were so invaluable to ancient cultures. Catalogs of these
medicines, like the “Ebers Papyrus” from Egypt3 and the Chinese Materia Medica,4
dating to 1500 and 100 BCE respectively, are some of the oldest records of remedies
and prescriptions known to man. The ancient Greek and Roman empires also
extensively documented remedies, including formulae and drug interactions, from
various natural sources. Much of these remedies were best documented by the Arabs,
who combined much of the Greek, Roman, Chinese, and Indian traditional remedies
with their own.29 These ancient remedies survived into the modern age, and as the
pharmaceutical industry evolved, it is no surprise that the plant-derived remedies were
among the first modern pharmaceuticals. In fact, the first large-scale, commercially
available drug was morphine, a secondary metabolite used in ancient remedies. While
the latex of Papaver somniferum seedpods has been collected since antiquity,
advancements in the extraction and identification allowed the active component to be
identified and produced commercially.30
Perhaps the most clinically relevant of therapeutics from traditional plant
remedies are plant-derived anti-malarial compounds. Malaria has long been one of
mankind’s most challenging health issues, heavily impacting the economic and social
growth of developing nations.31 The first major breakthrough in treatment was the
discovery of quinine from the bark of Chinchona officinalis, a plant used amongst
indigenous Amazonian peoples to treat fevers.29,32 Quinine became the first largely
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distributed drug treatment for malaria, and served as the basis for synthetic analogues,
chloroquinine and mefloquine, which replaced quinine as malaria treatments in the 20th
century.29 Following the emergence of resistance to quinine and its derivatives, ancient
medicines once again served as the scaffold for the next generation of effective antimalarial drugs, artemisinin. The Chinese Materia Medica contains descriptions of plantbased remedies used to treat severe fevers. Subsequently, artemisinin was isolated
from Artemisia annua,33 and its clinical importance as an effective treatment for malaria
quickly became apparent,34 and semi-synthetic artemisinin analogues remain as the
primary treatment for malaria today.35
Ancient plant-derived remedies have continued to produce many significant
commercial drugs. The secondary metabolite paclitaxel, most commonly known by its
brand name Paclitaxel, is one of the most important anti-cancer drugs in recent years.
Taxol, along with its precursors, was isolated from the leaves of various Taxus
species,36 and has been approved for use as a chemotherapy drug against multiple
types of cancer. Since its approval as a clinical drug, Paclitaxel has generated billions of
dollars, as well as a suite of semi-synthetically derived and generic chemotherapy
options.29 Ephedrine, first isolated from Ephedra sinica and described in Traditional
Chinese Medicine, is a potent anti-asthma medication (Figure 1.5.).29,37
1.2.2. Microbial Natural Product Pharmaceuticals
Just as plant remedies have led to important innovations in the therapeutic
industry, so too have microbial natural products produced some of the milestones drugs
in the modern age. Historically, microbial sources are underrepresented compared to
their plant counterparts in their use as therapeutics.
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Figure 1.5. Examples of landmark natural product drugs. Paciltaxel, isolated from the leaves of
Taxus brevifolia, photo by Jason Hollinger; artemisinin, isolated from Artemisia annua, photo by
Kristian Peters; (+)-ephedrine and (-)-ephedrine, isolated from Ephedra sinica, photo by Alex
Lomas.

As interest in secondary metabolite drugs increased, the breadth of research expanded
as well. In particular, the last century has shown a large boom in the number of
microbial-derived therapeutics, beginning with the landmark discovery of
penicillin.2,29,38,39 The penicillins, first isolated serendipitously by Alexander Fleming from
the filamentous fungus Penicillium notatum, became the first commercially available,
broad-spectrum antibiotic, first to aid in the war front of World War II, and later as the
most commonly used antibiotic.40
The wild success of the penicillin compounds as antibacterial agents ushered in
“The Golden Age of Antibiotics”, revolutionizing the search and production of antibiotics,
many of which were isolated from microorganisms. In addition to the penicillins and their
synthetic derivatives, cephalosporins, aminoglycosides, and tetracyclines are among
some of the most important microbial antibiotics. Like plant-derived drugs, microbes
10

have been found to produce chemistry with a broad range of disease targets. Anti-tumor
compounds like anthracycline, antiparasitics like ivermectin, and immunosuppressive
agents like cyclosporins and rapamycin demonstrate the broad range of biological
targets of microbial natural product therapeutics. Like plant-derived remedies, the world
of microbial natural products has resulted in some of the most important and significant
drugs of the last century, and continue to be a great source of new therapeutic agents. 29
1.2.3. Rise and Fall of Natural Product Pharmaceuticals
The field of new chemical entities (NCEs) introduced by the pharmaceutical and
research fields continues to be dominated by the influence of natural products. Of the
1,562 NCEs introduced over the last three decades, over 70% are related to natural
products, being natural products or their derivatives, containing a natural product
pharmacophore, or mimicking the behavior of natural products. 41 Furthermore, most
NCEs are small molecule drugs, with only ~10% being designated as large biologic
proteins and macromolecules (B), with 6% being vaccines (Figure 1.6.).41 Natural
products influences also constitute large portions of NCEs in the most clinically
prevalent disease areas. Anti-infective drugs, including antibiotics and antifungals,
represent almost a quarter of NCEs introduced over the last three decades. Of over 300
anti-infective NCEs, under 20% are purely synthetic, with natural product derivatives
and natural product derivatives making up the largest number of compounds.41
Similarly, anti-cancer NCEs are dominated by natural product derivatives. Fewer than
20% of anti-cancer NCEs introduced in the last thirty years have been solely synthetic,
a trend also seen in all anti-cancer drugs since the 1940’s.41
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Figure 1.6. All new chemical entities (NCEs) from 1981-2014, by type (above), all small molecule
NCEs by type (below), and description of NCE categories. 41

The impact of natural products, and specifically small molecule natural product drugs,
on new, active compounds is seen in many other disease areas, those effective against
diabetes, pain and central nervous system disorders, and parasites. Anti-viral NCEs
alone are not predominantly natural products and small molecules, with vaccines and
synthetic molecules making up most of the NCEs introduced in the last thirty years.
Despite this, many anti-viral NCEs introduced in the last five years include a natural
product pharmacophore, or are natural product mimics.2,41
Despite the dominating influence of natural products on the pharmaceutical
industry in the last several decades, there has been an undeniable decline in the
amount of natural product research, and natural product NCEs introduced in the most
recent 10-15 years. In the early to mid-1980’s, NCEs introduced reached some of its
highest numbers, with total new drugs introduced routinely surpassing 50 per year. In
12

each subsequent decade, the number of NCEs introduced dropped, from under 40 per
year in the 1990’s to under 30 per year in the 2000’s, with few outliers (Figure 1.7.).38
Despite decades of natural product therapeutic developments, the last several decades
have shown a decreased interest in natural products within pharmaceutical research.
The decline of research investment into natural products was brought about by a
shift in techniques for searching for new therapeutics. The standard screening and
development process of natural product research has many drawbacks: the expenses,
time, and effort invested into developing new, active compounds can be significant.
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Figure 1.7. Total number of small molecule natural products introduced per year over the last 30
years (1981-2014).41

Meanwhile, obtaining biodiversity to study can be rigorous, novel compounds become
more difficult to find, and scaling up production of new compounds is a critical hurdle of
drug development.42 Biological assay technology, however, has grown more efficient,
and there have been huge advancements in research of the genomic and molecular
targets of many disease organisms. The pace of high-throughput screening (HTS)
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against phenotypic and molecular target assays quickly outstripped the supply of single
natural products introduced for the first time, and the traditional natural product research
paradigm seemed incompatible with new screening technologies. In order to address
this issue, the pharmaceutical industry turned to large combinatorial libraries, consisting
of tens of thousands of synthetic compounds and derivatives, which could be
developed, maintained, and screened at a much faster rate than competing natural
product libraries.43 The shift to combinatorial chemistry greatly diminished the amount of
natural products research seen in recent decades.
1.2.4. The “New Golden Age” of Natural Products
While large, combinatorial libraries dominated much of the pharmaceutical
industry for the past twenty years, the return of new, clinically useful drugs has been
almost non-existent. Specifically, only two examples of de novo compounds approved
as drugs have been generated by the vast amount of combinatorial chemistry that
dominated the pharmaceutical industry (Figure 1.8.). The first, sorafenib, was
developed by Bayer and was first approved in 2005 as an anti-cancer drug, with activity
against various forms of cancer and carcinomas.41 Additionally, ataluren was reported
and approved in 2014 to treat rare genetic disorders.44 Despite the clinical relevance of
these two compounds, the success rate of combinatorial libraries pales in comparison to
the natural product NCEs introduced and approved over the same time period. From
2005-2014, the time frame during which both sorafenib and ataluren were approved,
~200 new drugs have been approved that would be classified as a natural product or
natural product derivative, or a synthetic drug containing or mimicking natural product
chemistry.41 With the underwhelming success of combinatorial libraries, a renewed
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investment in natural product chemistry has seen an increase in natural product NCEs
in the last few years, leading to a “New Golden Age of Natural Products” chemistry. 45

Figure 1.8. Chemical structures of ataluren (left) and sorafenib (right).

As the development of new natural products as therapeutics moves into the
future, traditional methodologies have continued to evolve, including new isolation and
characterization techniques, and new and unique sources of chemodiversity.
Established natural products have served as the inspiration for synthetic drugs, but
have also found new life in conjunction with other therapeutic methods. Paclitaxel, in
particular, has been at the forefront of combining natural products with nanoparticles.
Nanoparticular paclitaxel, in various forms, has been approved as a treatment as
recently as 2014, with the nanoparticle serving to increase the delivery and
effectiveness of the natural product.41 Similarly, there is a growing interest in natural
products serving as the building blocks or scaffolds for larger, synthetic molecules that
have drug efficacy.42 By far the most persistent challenge of natural product drug
discovery is simply finding natural product resources. Microorganisms may be easy to
culture, but inciting diverse chemistry can be difficult, leading to new efforts to physically
induce new and unique chemistry through culture and growth conditions.46,47 While
much natural product research, and indeed most of the examples already discussed,
are from terrestrial organisms, the marine world contains the largest, and largely
untapped, wealth of biodiversity, and is already well known as a source of new, novel
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chemodiversity.48 Finding new sources of chemodiversity, and evolving new techniques
to aid in compound development, remain critical to the continued success of natural
product therapeutics.
1.3.

Marine Derived Therapeutics
While terrestrial sources have undoubtedly been the major focus of most natural

products research, the marine environment holds the wealth of biodiversity on the
planet. The oceans cover approximately 70% of the Earth’s surface, with over half of the
total animal phyla described being fully or partially marine-dwelling.49 The knowledge of
marine-derived chemistry is certainly prominent throughout history: many cultures relied
on marine sources for herbal remedies and cuisine, most famously puffer fish (Fugu)
used in Japanese cuisine, and “Tyrian Purple” dye from Mediterranean mollusks being
used both as a dye and as a remedy for leukemia. Marine natural products research
has lagged behind terrestrial counterparts largely due to the difficulty of collection of
organisms, and though sporadic reports of marine-derived chemistry have occurred
throughout the last several centuries, marine natural product research didn’t flourish
until much more recently.48
Marine natural products play an important role in the therapeutics industry, with
several FDA approved agents being derived from marine sources. The impetus of
marine drug discovery research began with the isolation of several bioactive arabinosecontaining nucleosides from a Caribbean sponge Tethya crypta. These compounds
were groundbreaking, as they were bioactive without a deoxyribose or sugar moiety,
which was viewed as requirements for bioactivity at the time.50 These compounds led to
the development of marine derived, semi-synthetic FDA approved drugs such as
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cytosine arabinoside (Ara-C), an anti-tumor agent, and adenine arabinoside (Ara-A), an
antiviral agent. Most recently, Adcetris® was approved by the FDA in 2014 against
various kinds of leukemia. Adcetris® is an antibody-drug conjugate, the scaffold of
which is based on the dolastatins, cyclic and linear peptides isolated from sea hare
Dolabella auricularia.48 There are also myriad marine-derived drug agents throughout
the clinical pipeline, representing a large range of chemical classes and disease fields
(Table 1.1.), demonstrating the diversity of chemistry and biological activity present in
the marine environment.48,51
Table 1.1. Selected natural product and natural product derivatives that are FDA-Approved agents or
within the clinical pipeline.51
Clinical
Compound
Source
Chemical Class
Disease Area
Status
Name
Organism
FDA
Approved
FDA
Approved
FDA
Approved
FDA
Approved
FDA
Approved
FDA
Approved
Phase III
Phase III
Phase II
Phase II
Phase I
Phase I

Cytarabine
(Ara-C)
Vidarabine
(Ara-A)
Ziconotide

Sponge

Nucleoside

Cancer

Sponge

Nucleoside

Antiviral

Cone Snail

Peptide

Pain

Eribulin
Mesylate
(E7389)
Trabectedin
(ET-743)
Brentuximab
vedotin (SGN35)
Tetrodotoxin

Sponge

Polyketide

Hypertriglyceridermia

Tunicate

Alkaloid

Cancer

Mollusk

Antibody-drug
conjugate

Cancer

Unidentified
Microorganism
Tunicate

Glycoside

Pain

Cyclic depsipeptide

Cancer

Worm

Alkaloid

Fungus

Diketopiperazine

Cognition,
Schizophrenia
Cancer

Bryozoan
Soft Coral

Polyketide
Diterpene glycoside

Cancer, Alzheimer’s
Wound Healing

Plitidepsin
(Aplidine)
DMXBA (GTS21)
Plinabulin (NPI
2358)
Bryostatin 1
Pseudopterosins
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1.4.

Summary and Research Objectives

Secondary metabolism, though unessential for life, plays a critical role in the lifespan of
many organisms on Earth. The chemical properties of these secondary metabolites
have been exploited throughout mankind’s existence, and in modern times, much of the
advancements in treating disease is owed to natural products chemistry. Though
interest in traditional natural products research has waxed and waned over the years,
the chemical potential present in nature is undoubtable, and while much of the terrestrial
world has been mined as chemodiversity sources, the marine environment has largely
lagged behind. However, the marine environment, with its larger degree of biological
and chemical diversity, continues to serve as a source of new chemistry in the ongoing
fight against human pathogens.
As the search for new, biologically active chemistry continues, it is key to search
for unique biodiversity, and utilize cutting edge techniques to make discovery and
isolation of new compounds more efficient. The following chapters seek to do that, by
mining both marine mangrove-associated fungi, and cold water sponges for new
chemistry, and utilizing advanced mass spectrometric techniques to guide dereplication
and structural elucidation.
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CHAPTER TWO:
MINING FLORIDIAN MANGROVE ENDOPHYTIC FUNGI FOR ANTI-INFECTIVES

2.1.

The Hunt for Antibiotics
2.1.1. The ESKAPE Pathogens
One of the greatest challenges facing human health in the modern world is the

rise of pathogenic drug resistance. In particular, antibiotic resistance in bacterial
pathogens has been on the rise for decades, leading to one of the largest public health
issues in the developed world. The discovery of penicillin in the 1940s inspired the
“Golden Age of Antibiotics”, with new and safe antibiotics flooding the market. 1 These
antibiotics represent a great structurally diversity, and inhibit bacterial growth through a
number of mechanisms, including sodium channel blocking and cell wall disruption,
among others.2,3 Despite the chemical diversity among marketed drugs, the greater
genetic flexibility of human pathogens has resulted in the now-predictable development
of antibiotic resistance. Coupled with the rise of antibiotic resistance was the general
decline in new market antibiotics. In 2007, the number of newly introduced antibiotics
was less than half the number almost thirsty years prior (Figure 2.1.).1 The rise of drug
resistance, and the decline of new drugs to combat disease, has resulted in one of the
most health prevalent concerns of the modern world.
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Figure 2.1. Decline in new antibiotics from 1983-2007.1

The most prevalent and deadly of antibiotic resistant bacterial pathogens are the
six ESKAPE pathogens.1 These pathogens, Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa,
and Enterobacter species, represent both gram-positive and gram-negative bacteria,
are the most common nosocomial bacterial infections, and effectively “escape” the
effect of antibiotic drugs.4 Chief among the ESKAPE pathogens, methicillin-resistant
Staphylococcus aureus (MRSA) (Figure 2.2.), represents the largest and most fatal
bacterial infection in US hospitals. As of 2007, MRSA causes ~18,000 deaths per year,5
more than both HIV/AIDS and tuberculosis combined,1 with the largest proportion of
deaths occurring in infant or very old patients, who typically undergo longer hospital
stays and have more vulnerable immune systems.6 To further complicate the fight
against bacterial pathogens, many pathogens have developed pan-antibiotic resistance,
and exist in varied morphological forms, like biofilms and free-living forms, that require
drugs with different molecular targets.7 Because of their virulence, morphological
variety, and modes of transmission, the ESKAPE pathogens are some of the most
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important and intensely studied bacterial pathogens, with national investment in
research exceeding $800 million annually.4

Figure 2.2. SEM Images of MRSA and vancomycin-resistance Enterococcus faecium (VRE). (A)
A Scanning-electron microscope (SEM) image of MRSA cell clusters enmeshed with human red blood
cell. Photo from National Institute of Allergy and Infectious Diseases. (B) Three-dimensional computer
generated image of VRE cells based on SEM images of bacterial cells, Photo by James Archer, CDC
Public Health Image Library.

2.1.2. Mangrove Forests
Mangrove environments possess a wealth of biological and chemical diversity.
Mangrove forests exist on the interface of terrestrial and marine systems, and, second
only to coral reefs, are the largest source of biodiversity in the marine environment. 8 No
small part of the biodiversity in mangrove forests are microbial. Surveys of mangrove
forests around the globe found hundreds of microbial species, including actinomycetes,
bacteria, and fungi, with a range of morphologically and ecologically different members
of each clade.9 The endophytic microbial community can also range from terrestrial
species in the upper and inland portions of individual mangrove trees, to marineexclusive species within the trees nearest and submerged in the water.9 In addition to
biological stress, mangrove forests face harsh environmental conditions. Mangrove
forests are considered fringe environments, and environmental conditions like water
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level, rain fall, temperature, and salinity varying greatly over the course of days or
hours.10 The resulting ecosystem is environmentally stressful with harsh competition
within the endophytic microbes, ideal for unique biological and chemical diversity. 9
The Floridian mangrove forests represent a highly diverse biological system.
Weather patterns are highly variable across the state, with average rainfall varying from
45-60 inches per year depending on location, with heavy storm surges dropping up to 9
inches of rain in a matter of hours. Similarly, the landscape ranges drastically from the
shallow, clay and limestone based soil in the northern portions of the state to swampy,
highly acidic environments in the southern Everglades and surrounding areas. 10 These
variable conditions make for a diversity of micro-ecosystems within the total mangrove
forests found along the Gulf of Mexico, and is reflected in the flora and fauna of the
forests.

Figure 2.3. Floridian mangrove species. Red mangroves (A) with aerial prop roots, black
mangroves (B) with pneumatophores emerging from the soil, and white mangrove leaves (C).
Photo: Cathleen Bester, Florida Museum.

Generally, Floridian mangroves are dominated by red mangroves (Rhizophora mangle),
noticeable for their aerial prop roots, and black mangroves (Avicennia germinas), which
produce pneumatophores, modified roots that allow oxygen exchange even when
mostly submerged in water. A less common species, the white mangrove (Laguncularia
racemose) is also present in many Floridian forests, and are the most morphologically
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diverse of the three mangrove species (Figure 2.3.). In addition to mangrove, many
associated flora species, including buttonwood (Conocarpus erectus) and leatherferns
(Acrostichum sp.), as well as myriad insect predators.11 The Floridian mangrove forests
contain a wealth of biological diversity, and a particularly varied and harsh competitive
environment for microbial species.
2.1.3. Exploring Fungal Endophyte Chemistry
Mangrove forests, and specifically their endophytic microbial communities, have
been well studied as sources of new, bioactive chemistry. Compounds produced by
mangrove fungal endophytes are structurally diverse, including polyketides, terpenes,
peptides, and quinine derivatives to name a few.12 The chemistry from mangrove fungal
endophytes exhibits biological activity against a range of disease targets. Most
prominent are antimicrobial compounds, including antifungals13 and antibiotics.14 They
have also been a source of anti-parasitic compounds, including compounds active
against the malarial parasite,15 and feeding deterrents against parasites and insect
larvae that feed on the mangroves trees.16,17 There have also been several compounds
isolated with biological activity in various cancer-related bioassays, including cancer cell
lines, carcinomas, and angiogenesis.17,18
One of the largest challenges in culturing fungal endophytes in the lab is
maintaining the biosynthesis of secondary metabolites. In nature, many biologically
active secondary metabolites are produced to repel microbial competitors. When
isolated in the lab, endophytic fungi have little need to produce antibiotic compounds,
and so production is downregulated or halted altogether.19 The ability to reactivate these
silent pathways, and to activate biosynthetic gene clusters that may be latent even in
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nature, are critical to accessing the full wealth of chemical diversity that endophytic fungi
are capable of producing.
Historically, activation of these biosynthetic pathways has been achieved by
molecular targeting, or by cultivation-based techniques.19 Molecular targeting takes
advantage of the advances in whole-genome sequencing, by identifying and cloning
secondary metabolism gene clusters into host organisms. This research has resulted in
several new compounds being identified from even exhaustively studied strains like
Streptomyces sp., including aspoquinoline A and B (Figure 2.4.).20 Cultivation-based
techniques can include introducing environmental stressors and novel media types
during culture to activate secondary metabolic pathways,21,22 or introducing the target
organism to co-culturing with another microorganism. The presence of a bacterial
pathogen has been shown to elicit the biosynthesis of otherwise down-regulated
secondary metabolites, as demonstrated with the discovery of pestalone from a fungalbacterial co-culture (Figure 2.4.).23 Despite the success of both techniques, they each
come with drawbacks. Molecular targeting approaches are hindered by the difficulty in
identifying and replicating secondary metabolic gene clusters, while culture-based
methods can be time-intensive while being highly variable in their success rate.19

Figure 2.4. Chemical structures of aspoquinoline A, pestalone, and tenuipyrone. Aspoquinoline A
(left) was discovered using molecular targeting approaches, pestalone (center) using fungalbacterial co-culturing, and tenipyrone (right) using small molecule epigenetic modulators.
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Epigenetic modulation has appeared as a highly successful method of inciting
silent secondary metabolic pathways in laboratory culture conditions. Whole-genome
sequencing of fungi has shown that many secondary metabolic gene clusters occur in
distal regions of the genome where gene transcription is controlled epigenetically
through processes like histone deacetylation and DNA methylation.19 Williams and
colleagues first described utilizing small molecule epigenetic modulators in fungal
culturing to alter the epigenetic transcription of these gene clusters, resulting in an
upregulation of secondary metabolites by the pure fungal isolates.19 This work was
significant because it allowed isolated fungal strains to be grown in simple, fast culture
conditions, while still producing higher concentrations of new secondary metabolites.
This methodology has since become significant in fungal natural products research,
yielding many new compounds with anti-infective biological activity.24,25

Figure 2.5. Comparison of methods to activate silent fungal biosynthetic gene clusters (BGC). (A)
Example of co-culture between a fungal and bacterial isolate. (B) Identification, cloning, and
expression of fungal gene clusters in a host organism. (C) Activation of BGC in epigenome using
small molecule epigenetic modulators. Activated BGC results in the biosynthesis of secondary
metabolites.26
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2.2.

Research Objectives
In the face of rising drug resistant bacterial pathogens, a need for new sources of

bioactive chemistry is paramount. Mangrove systems represent harsh and competitive
environments, particularly for the endophytic microorganisms. While fungal endophytes
in mangroves have been proven to be great chemodiversity sources, the vast majority
of research has been conducted on Asian, Indian, and Indo-Pacific mangrove forests.
Floridian mangrove forests, conversely, are virtually untapped for their biological and
chemical diversity. In order to access the wealth of chemical potential present in these
systems, we here report the collection and isolation of Floridian mangrove endophytic
fungi, and a high-throughput screening (HTS) of their extracts against the ESKAPE
pathogens. In order to effectively access these fungi’s full biosynthetic potential, small
molecule epigenetic modifiers were utilized in culture conditions. Following this HTS,
select fungi with potent activity against one or more of the ESKAPE pathogens were
grown in large scale and studied for their bioactive chemistry.
2.3.

High-Throughput Screening of Epigenetically Modulated Mangrove
Endophytes
2.3.1. Collection and Isolation of Fungal Strains
Mangrove tissues were collected in the field in various microclimates throughout

Florida. Collection sites ranged from urban areas, remote locations in the Florida
Everglades, and in and around the islands of the Florida Keys (Table 2.1., Figure 2.6.).
Tissue was collected from stem, roots, bark, and leaves of all three types of Floridian
mangroves (R. mangle, A. germinas, and L. racemose), as well as mangrove
associated flora (C. erectus) and marine sediment in the mangrove forests.
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Table 2.1. Collection Sites from Florida
Mangrove Forests
Collection
Site
Everglades
National Park
(2010)
Courtney Campbell
Causeway
(Tampa, FL) 2010
CQ (2010)
Everglades
National Park
(2012)
Keys Marine Lab
(2012)
Howard-Franklin
Bridge
(Tampa, FL) 2014
Keys Marine Lab
(2014)

Code
Name
EG10

CC10

CQ10
EG12

KML12
HF14
Figure 2.6. Map of Florida collection sites.
©GoogleEarth

KML14

Procedures for collection of mangrove tissue and isolation of fungal strains have
been previously established in our lab to maximize growth of hardy fungal endophytes
(Appendix I).24,27 Briefly, mangrove tissue is surface-sterilized in the field, and portions
of tissue are embedded in various types of solid, selective the growth media. Growth
media vary in carbohydrate source (dextrose, glycerol, potato dextrose, actinomycete
agar) and presence of antibiotics and antifungals (chloramphenicol, cycloheximide,
nystatin) to discourage the growth of prolific fungal strains and encourage the growth of
slower, hardier fungal strains. Pure fungal strains are obtained after iterative rounds of
isolation, and fungal isolates are frozen in glycerol for long-term storage.
2.3.2. Culture, Extraction, and Screening of Fungal Isolates
After isolation, fungal isolates were grown in small scale and extracted.
Procedures for the growth and extraction of fungal isolates was developed in our lab, 24
and were adapted for HTS of thousands of fungal isolates. In addition to non33

modulated, “control” growth conditions, each isolate was also grown in the presence of
one of two small molecule epigenetic modulators. Sodium butyrate, a histone
deactylase inhibitor (HDACi), and 5-azacytidine, a DNA methyl transferase inhibitor
(DNMTi) were selected as modulators due to their cost and reported use in literature
(Figure 2.7).19,24 For each growth condition, several portions of the fungal mat were
submerged in an untreated dextrose broth, or a dextrose broth containing the HDACi or
DNMTi modulator, and transferred onto unprocessed rice.

Figure 2.7. Chemical structures of sodium butyrate (left) and 5-azacytidine (right).

Fungal cultures were incubated for 21 days, and extracted with ethyl acetate (EtOAc).
Extracts were dried down and solvated in dimethyl sulfoxide (DMSO) at 5 mg/mL. A
portion of each extract was frozen and stored for long-term use, while a 150 µL aliquot
of each extract was plated for biological testing against the ESKAPE pathogens.
2.3.3. Results of High-Throughput Screening
Over the course of the two year HTS of mangrove fungal endophytes,
approximately 2700 fungal isolates were collected from several mangrove forests
throughout Florida. When cultured in the epigenetically modulated or unmodulated
growth conditions, they produced 8000 distinct fungal extracts. In a screen for biological
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activity against the ESKAPE pathogens, 578 extracts displayed activity, a 7.5% activity
rate for our whole fungal library. This activity rate is in a desirable range for a HTS of
similar size, indicating that extraction and biological screening did not produce an
overabundance of falsely positive results. Of the 578 active samples, untreated,
“control” growth conditions accounted for 191 extracts (~33%), while HDACi and DNMTi
treated growth conditions accounted for 169 (~29%) and 218 (~37%) of the active
extracts, respectively. Altogether, the addition of epigenetic modulators resulted in an
additional 20% increase in the activity rate when compared to control-only activity rate
(Figure 2.8.). Biological activity of the extracts was diverse, with activity against all six
of the ESKAPE pathogens present, most commonly S. aureus, and at a range of
effective concentrations.

Figure 2.8. Activity rate of HTS of mangrove fungal endophytes. (A) Of the ~8000 extracts
screened, 7.5% displayed biological activity. (B) Of the ~600 active samples, ~33% were active in
at least the control growth treatment while epigenetic modulation accounts for ~30% and ~37% of
total active extracts.

Epigenetic modulation markedly improved the biological activity of the extract
library (Figure 2.9.). Of the 578 active extracts, 191 were active in only the control
growth culture, while 101 were active in only the epigenetically modulated growth
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conditions. Of the 101 modified-only active extracts, 48 were active in only the HDACi
growth treatment, and 53 were active in only the DNMTi growth condition. In addition to
inducing activity, epigenetic modulation also increased the potency of many extracts. Of
the active extracts, 72 had significantly improved biological activity in only one of the
modified growth conditions.

Figure 2.9. Effects of epigenetic modulation on biological activity. (A) Epigenetic modulation
induced biological activity in ~100 fungal isolates. Of these, 48 were in the HDACi treatment, and
53 were in the DNMTi treatment. (B) In 72 fungal isolates, epigenetic modulation increased the
potency compared to the control growth treatment, with increase in activity evenly distributed
between modified treatments.

Screening of the fungal extract library showed a strong source of biologically
active extracts against the six ESKAPE pathogens. Introduction of epigenetic
modulators significantly increased the diversity and potency of the fungal extract library.
The resulting library represents a robust library of extracts that can be studied for their
chemistry.
2.4.

Chemical Investigation of Phomasetin sp. and Alternia sp. Fungal Isolates
2.4.1. Selection and Growth of Select Fungal Isolates
Following HTS of our fungal endophyte library, select fungi were prioritized to be

grown in large-scale culture and studied for their chemistry. Prioritization was based on
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the potency and selectively relative to the rest of the extract library. From the list of
prioritized fungi, two, KML14-75MG-C8 and HF14-17C-3B, were selected for further
study. The former, isolated from the leaf of an exotic Australian mangrove relative,
Pandanus spiralis, collected in the Fairchild Botanical Gardens in Miami, FL, showed
highly potent activity against S. aureus (IC50= 1 µg/mL) in all three culture conditions.
The latter fungus was isolated form the leaf of a red mangrove (R. mangle) in Tampa,
FL, and showed selective activity against S. aureus (IC50=10 µg/mL) in the DNMTi
growth culture.
Fungal isolates were re-grown in large scale to facilitate chemical investigation. A
larger selection of fungal biomass was grown in a larger volume of rice media and
epigenetic modulation broth, representing a ten-fold increase in scale compared to the
HTS culture conditions. Fungal cultures were incubated for 21 days, before extraction
for 24 hr in a 1:3 methanol (MeOH): ethyl acetate (EtOAc) mixture. Following this first
extraction period, the fungi were extracted with EtOAc for two more 24 hr periods.
Biological activity was verified in the crude extracts before they were subjected to
chromatographic separation guided by biological activity.
2.4.2. Isolation and Characterization of Equisetin and Ent-equisetin
The crude extracts of all three culture treatments of KML14-75MG-C8 were first
partitioned between EtOAc and a 1:3 MeOH:H2O layer. The EtOAc layers were then
subjected to Medium Pressure Liquid Chromatography (MPLC) to yield ~7 fractions.
While several of these fractions were active against S. aureus, each extract had a single
fraction that maintained the potent activity (1 μg/mL) desired. A Liquid
Chromatography/Mass Spectrometry (LC/MS) analysis of these fractions revealed a
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nearly identical chemical profile between all three treatments, and so the active MPLC
fractions were combined and carried forward to further separation with High
Performance Liquid Chromatography (HPLC). Biological activity was used to guide
initial normal phase (NP) HPLC with Hexanes and EtOAc. After NP HPLC, reverse
phase (RP) HPLC with water and acetonitrile (ACN) was used to purify two closely
eluting compounds, labeled MAK 5 and MAK 7 (Scheme 2.1).
Proton Nuclear Magnetic Resonance (1H NMR) spectroscopy revealed nearly
identical spectra for MAK 5 and 7, while High Resolution Electrospray Ionization Mass
Spectrometry (HRESIMS) revealed the same mass for each compound (m/z 374.4940
[M+H]+, m/z 374.4940 [M+H]+), matching the literature value of two diastereomers,
equisetin (1) and ent-equisetin (2) (Figure 2.10.), two potent cytotoxins isolated
exclusively from Phomatsetin sp.28 A full 2D NMR data set was obtained for each
compound in order to verify the identities of each compound.

Figure 2.10. Chemical structures of equisetin (1) and ent-equisetin (2). Important COSY (bold)
and HMBC (arrow) correlations used to verify the structures are shown.
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Table 2.2. shows the 1H and 13C NMR data for MAK 5 and MAK 7 in comparison
to 1 and 2. Prominent in each were several methyl groups, two olefinic protons, and
protons on a nitrogen-bearing methyl (δH 3.05). Long-range 2D NMR data (HMBC,
COSY) were used to construct and connect spin systems within the molecule (Figure
2.10). Both 1 and 2 notably contained a tetramic acid substructure, with the nitrogenbearing methyl correlating to two carbonyls (δC 177.0 and 200.2), as well as an alkyl
chain terminating in a primary alcohol, indicated by the proton and carbon chemical
shifts of positions 5’, 6’, and 6’’. Additionally, a decalin ring system was determined,
containing a endo-cyclic alkene at position 4 and 5, and a trans- exo-cyclic alkene at
position 3. There were no significant long-range correlations between the two portions
of these substructures, however, both correlated to quaternary carbons at position 1
and 3’. While position 1 had a chemical shift indicative of a fully substituted alkene (δ C
100.0), position 3’ had a significantly higher chemical shift (δC 200.7), which, together
with HRESIMS data, confirmed the presence of an enol alkene connecting the tetramic
acid and decalin portions of the molecule. Stereochemistry of both was determined by
comparison of J-coupling constants at key positions to literature values of synthetic
equisetin and ent-equisetin.28 The J-coupling constants at positions 3, 4, 5’, 6’, 6’’, and
7’’ indicated that MAK 5 was equisetin (1), while MAK 7 was ent-equisetin (2),
differentiated by the stereochemistry of substituents around the decalin ring system.
After purification and structural verification of 1 and 2, a final round of biological
assay found the compounds to be active against S. aureus at 1 μg/mL (2.67 µM) and 10
μg/mL (26.70 µM), respectively. However, both compounds are reported in the literature
as known cytotoxins.

39

Table 2.2. 1D NMR data for MAK 5, MAK 6, equisetin, and ent-equisetin in CDCl3.
Pos

δCb

δH (m, J(Hz))a

δCb

δH (m, J(Hz))a

δCb

δH (m, J(Hz))a

1
2
3e

MAK 5
190.7
48.8
45.0

-----

----3.32 (br d, 1 H)

MAK 7
190.7
500.0
45.0

-----

3.32 (br s, 1 H)

Equisetin
190.6
48.4
44.6

3.35 (br s, 1 H)

4

126.6 or 129.9

5.40 (br s, 1 H)

127.1 or 126.2

5.40 (br s, 1 H)

126.6 or 129.9

5.40 (br s, 1 H)

5
6a
7a
7e
8a
9a
9e
10a
10e
11a
12

126.6 or 129.9
38.6
42.2

130.4 or 129.8
38.4
41.9

39.6
13.7

5.40 (br s, 1 H)
1.84 (br t, 8.0, 1 H)
0.90 (q, 12.0, 3 H)
1.81 (br d, 12.0, 1 H)
1.48 (m. 1 H)
1.11 (q, 9.0, 1 H)
1.76 (br m, 1 H)
1.04 (q, 12.0, 1 H)
1.96 (br d, 12.0, 1 H)
1.66 (br t, 11.0, 1 H)
1.46 (s, 3 H)

126.6 or 129.9
38.5
42.0

40.0
14.3

5.40 (br s, 1 H)
1.83 (m, 1 H)
0.90 (m, 1 H)
1.79 (m, 1 H)
1.52 (m, 1 H)
1.09 (q, 9.5, 1 H)
1.75 (br m, 1 H)
1.09 (q, 12.0, 1 H)
1.97 (br m, 1 H)
1.69 (br s, 1 H)
1.47 (br s, 3 H)

40.0
14.5

5.42 (br s, 1 H)
1.83 (m, 1 H)
0.89 (m, 1 H)
1.79 (m, 1 H)
1.52 (m, 1 H)
1.09 (q, 9.5, 1 H)
1.75 (br m, 1 H)
1.09 (q, 12.0, 1 H)
1.97 (br m, 1 H)
1.69 (br s, 1 H)
1.47 (br s, 3 H)

13

130.8

5.17 (m, 1 H)

130.4 or 129.8

5.17 (dd, 15.0, 9.0, 1 H)

131.0

5.17 (m, 1 H)

14
15
16
2'
3'
4'
5'

127.0
17.8
22.5
177.0
100.0
200.2
66.1

5.25 (m, 1 H)
1.52 (d, 5.0, 3 H)
0.92 (d, 6.5, 3 H)

127.1 or 126.2
18.2
22.5
176.7
99.8
198.8
66.4

5.25 (dq, 15, 6.5, 1 H)
1.56 (d, 6.5, 3 H)
0.92 (d, 6.5, 3 H)

127.0
17.8
22.5
177.0
100.1
200.0
66.0

5.25 (m, 1 H)
1.52 (d, 5.0, 3 H)
0.92 (d, 6.5, 3 H)

6'

60.3

6''
7'
enol H

27.2

33.5
35.7
28.4

------3.67 (br t, 5.0, 1 H)
4.07 (br d, 11.0, 1
H)
3.9 (dd, 11.4, 5.0, 1
H)
3.06 (s, 3 H)

33.3
35.5
28.1

60.0

27.2

------3.67 (dd, 5.0, 3.0, 1 H)
4.07 (dd, 11.0, 3.5, 1 H)
3.90 (dd, 12.0, 5.0, , 1
H)
3.07 (s, 3 H)
17.3 (s, 1 H)

33.5
35.7
28.1

60.5

27.2

------3.65 (br t, 3.5, 1 H)
4.05 (br d, 11.0, 1 H)
3.83 (dd, 12.0, 3.0, 1
H)
3.04 (s, 3 H)

----------a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 13C recorded at 125 MHZ.
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δCb
Ent-Equisetin
190.7
48.0
44.6
127.1 or
126.2
130.4 or
129.8
38.5
42.0
33.3
35.6
28.0
39.9
14.0
130.4 or
129.8
127.1 or
126.2
18.2
22.6
176.8
100.0
198.8
66.6
60.0

27.0

---

δH (m, J(Hz))a

----3.36 (br s, 1 H)
5.42 (m, 1 H)
5.41 (m, 1 H)
1.83 (m, 1 H)
0.90 (q, 12.0, 3 H)
1.80 (m, 1 H)
1.48 (m, 1 H)
1.11 (q, 12.0, 1 H)
1.77 (br m, 1 H)
1.04 (m, 1 H)
1.96 (br m, 1 H)
1.66 (m, 1 H)
1.45 (s, 3 H)
5.16 (dd, 15.0, 9.0 1
H)
5.24 (dq, 15.0, 6.0, 1
H)
1.56 (d, 6.5, 3 H)
0.92 (d, 6.5, 3 H)

------3.66 (t, 3.5, 1 H)
4.05 (dd, 11.0, 3.0, 1
H)
3.85 (dd, 12.0, 3.5, 1
H)
3.05 (s, ,3 H)
17.3 (s, 1 H)

Scheme 2.1. Isolation of MAK 5 and MAK 6.

2.4.3. Isolation and Characterization of Alternaria sp. Metabolites
The second fungus selected for chemical investigation, HF14-17C-3B was grown
in large scale identically to KML14-75MG-C8, but only in the DNMTi growth treatment.
Following a partition between EtOAc and 1:3 H2O:MeOH, the EtOAc layer was
subjected to NP MPLC to yield eight fractions. Two fractions showed activity against S.
aureus; the first (G) was active at 10 μg/mL, while the second (H) was active at
100 µg/mL. Initial separation of both fractions was performed with RP HPLC with H 2O
and MeOH. Following a final round of purification with H2O and ACN, two compounds
(MAK 9, MAK 10) were isolated from fraction G, while a third (MAK 11) was isolated
from fraction H (Scheme 2.2).
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Scheme 2.2. Isolation of MAK 9, 10, and 11.

MAK 9 displayed several 1H and 13C NMR signals similar to 1 and 2, in particular
the ketone (δC 179.8 and 191.8) and enol (δC 99.9 and 198.9) carbon signals, and
signals in the olefinic region (Table 2.3.). Noticeably absent, however, was the nitrogenbearing methyl present in 1 and 2, and MAK 9 displayed an additional two olefins.
HRESIMS for MAK 9 (m/z 400.5231 [M+H]+) matched altersetin (3),29 a compound
structurally similar to 1 and 2. 2D NMR was used to confirm the structure of MAK 9.
Similar to 1 and 2, MAK 9 also has a tetramic acid portion, though containing a
secondary amide and alcohol. Long-range HMBC correlations between the protons of
the alcohol side-chain and the 2’ and 4’ position carbonyls verified the tetramic acid.
The decalin ring portion was largely confirmed by COSY correlations. Noticeably, there
is a conjugated exo-cyclic trans alkene system connected to the decalin ring at position
3. The confirmation of the conjugated system was confirmed to match that of 3 based
on the J-coupling constants of the alkene protons.
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Table 2.3. 1D NMR data for MAK 9 and altersetin (3) in DMSO-d6.29
Pos

δCb

δH (m, J(Hz))a

MAK 9

δCc

δH (m, J(Hz))a

Altersetin

NH

---

9.22 (br s, 1 H)

---

9.20 (br s, 1 H)

2

182.8

179.8

3

100.0

4

191.5

-------

191.5

-------

5

66.9

3.60 (br s, 1 H)

66.8

3.61 (br s, 1 H)

6

199.1

198.6

7

45.5

-----

48.6

-----

8

39.1

1.55 (m, 1 H)

39.0

1.56 (m, 1 H)

9a

28.0

1.89 (m, 1 H)

27.9

1.90 (m, 1 H)

9e
10a

99.7

1.03 (m, 1 H)
36.0

10e

1.03 (m, 1 H)

0.99 (m, 1 H)

35.6

1.72 (m, 1 H)

1.00 (m, 1 H)
1.70 (m, 1 H)

11

33.0

1.51 (m, 1 H)

33.1

1.50 (m, 1 H)

12a

42.0

0.82 (m, 1 H)

42.0

0.80 (m, 1 H)

12e

1.82 (m, 1 H)

1.80 (m, 1 H)

13

38.0

1.80 (m, 1 H)

38.4

1.80 (m, 1 H)

14

131.0

5.45 (m, 1 H)

130.6

5.45 (dm, 1 H)

15

126.2

5.36 (m,, 1 H)

126.2

5.35 (m,, 1 H)

16

45.5

44.2

17

130.0

18

131.5

19

131.5

20

128.5

3.43 (m, 1 H)
5.24 (dd, 14.0, 4.0, 1
H)
5.71 (dd, 10.9, 3.0, 1
H)
5.88 (dd, 11.0, 3.0, 1
H)
5.50 (dq, 15.2, 5.5, 1
H)

128.3

3.45 (m, 1 H)
5.24 (dd, 14.0, 3.5, 1
H)
5.70 (dd, 10.9, 3.5, 1
H)
5.90 (dd, 10.9, 3.3, 1
H)
5.50 (dq, 15.4, 6.0, 1
H)

21

18.9

1.64 (d, 6.7, 3 H)

18.1

1.64 (d, 6.7, 3 H)

22

14.0

1.35 (s, 3 H)

13.8

1.35 (s, 3 H)

23

22.7

0.86 (d, 7.0, 3 H)

22.7

0.85 (d, 6.7, 3 H)

24

21.1

3.90 (m, 1 H)

21.0

3.91 (m, 1 H)

25

66.1

1.20 (d, 6.0, 3 H)

65.9

1.17 (d, 6.3, 3 H)

131.1
131.6
131.6

a 1H

NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration). b 13C
recorded at 125 MHz.

HMBC correlations linked the two portions of the molecule via an enol identically to 1
and 2, thus confirming the structure of MAK 9 to be altersetin (3) (Figure 2.11.).
Relative stereochemistry was confirmed based on the 1H NMR shift and J-coupling
values of positions 3, 4, 5’, 6’, 6’’ ,and 7’’ as compared to literature values. 29
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Figure 2.11. Chemical Structures of altersetin (3), altertoxin I (4), and pyrophen (5). Important
COSY (bold) and HMBC (arrow) correlations are shown.

A second compound, MAK 10, was isolated in a similar method to compound 3. It
was structurally very different from previously isolated compounds, with the 1D NMR
spectra indicating the presence of multiple ketones and phenolic protons (Table 2.4.).
The HRESIMS for MAK 10 (m/z 353.3433 [M+H]+) matched that of altertoxin I (4),30 a
toxin isolated from strains of Alternaria sp., the same genus that produces 3. The
HRESIMS for MAK 10 displayed a prominent base peak (m/z 317.3424 [M+H-2H2O]+)
indicative of a dehydration of the secondary and tertiary alcohols present in 4, which
generates an additional aromatic ring in the resulting fragment. The structure of MAK 10
was verified by 2D NMR (COSY, HMBC). Long-rage HMBC correlations indicated that
the two aromatic rings were connected to one another, and that each was adjacent to a
carbonyl carbon. The chemical shift of the phenolic protons (δH 12.34 and 12.69)
indicated that they are located in the β-position to the carbonyls (δC 202.0, 204.9) and
are capable of hydrogen bonding. COSY correlations indicated a spin system of an alkyl
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chain bridging the two carbonyl, with a secondary and tertiary alcohol present (Figure
2.11.). The spectroscopic data verified the structure of MAK 10 to be identical to
altertoxin I(4).
Table 2.4. 1D NMR data for MAK 11 and altertoxin I (3).30
Pos

δCc

δH (m, J(Hz))a

δCb

MAK 11

δH (m, J(Hz))a

Altertoxin

1

132.6

7.83 (d, 8.7, 1 H))

132.7

7.87 (d, 8.8, 1 H)

2

120.0

7.07 (d, 8.8, 1 H)

119.5

7.01 (d, 8.8, 1 H)

3

162.3

162.3

3a

116.9

4

204.9

-------

205.0

-------

5e

33.9

2.69 (dt, 16.7, 3.1, 1 H)

34.0

2.65 (dt, 15.0, 3.0, 1 H)

5a
6a

116.9

3.17 (m, 1 H)
34.4

6e

3.17 (m, 1 H)

2.43 (td, 14.3, 4.1, 1 H)

34.5

3.01 (m, 1 H)

2.43 (dt, 13.0, 3.0, 1 H)
3.17 (m, 1 H)

6a

69.2

---

69.2

---

6b

51.9

3.07 (d, 5.5, 1 H)

51.9

3.09 (d, 9.0, 1 H)

7

66.1

4.76 (m, 1 H)

66.1

4.78 (ddd, 12.0. 9.0, 5.0, 1 H)

8a

47.7

2.91 (dd, 16.1, 12.0, 1 H)

47.7

2.94 (dd, 16.0, 5.0, 1 H)

8e

3.08 (m, 1 H)

3.07 (dd, 16.0, 4.0, 1 H
202.0

162.0

---------

162.0

---------

11

117.6

7.02 (d, 8.8, 1 H)

117.5

6.92 (d, 8.8, 1 H)

12

132.4

7.81 (d, 8.7, 1 H)

132.4

7.82 (d, 8.8, 1 H)

12a

124.4

124.1

12b

122.7

12c

135.4

-------

-------

3-OH

-----

12.69 (s, 1 H)

-----

9

202.0

9a

116.1

9b

139.1

10

10-OH

117.4
139.1

122.7
135.5

12.34 (s, 1 H)

12.7 (s, 1 H)
12.4 (s, 1 H)

a 1H

NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C
recorded at 125 MHz. c 13C shifts are taken from HMBC spectrum.

The final compound isolated from HF14-17C-3B was MAK 11. MAK 11 was
significantly smaller in size than the other compounds isolated from endophytic fungi.
The 1H NMR spectrum of MAK 11 indicated the presence of two aromatic rings, a

45

methoxy, and a methyl ketone (Table 2.5.). The HRESIMS of MAK 11 (m/z 287.3144
[M+H]+] matched that of pyrophen (5), an Alterania sp. metabolite.31 The structure of
MAK 11 was verified using 2D NMR (COSY, HMBC). COSY and HMBC correlations
indicated two aromatic rings, one singly substituted, connected by a two-carbon alkyl
chain. The second aromatic ring was heterocyclic, contain an oxygen and an exocyclic
carbonyl (δC 162.9). The second aromatic ring was determined to contain a m-methoxy
substituent. Attached to the alkyl bridge is a secondary methyl amide (Figure
2.11.).The 2D NMR data verified the base structure of MAK 12, while the relative
stereochemistry was determined using 1H NMR and optical rotation. Pyrophen, and its
stereoisomers isopyrophen, vary only in the chirality of position 7. Though the chemical
shift of the proton at position α is unchanged in both stereoisomers, the shift of the
amide proton adjacent differs significantly. The amide proton in pyrophen (δH ~6.0) is
significantly upfield of the amide proton in isopyrophen (δH ~7.0), a difference supported
by the optical rotation of pyrophen [𝛼]25
𝐷 values of -13.8 for pyrophen and +1.1 for
isopyrophen.32 The chemical shift of the amide proton (δH 5.96) and optical rotation
([𝛼]25
𝐷 =+1.4) verified MAK 12 as pyrophen (5).
The three metabolites isolated from HF14-17C-3B have all been previously
reported from Alternaria sp. Once purified, the compounds were submitted for biological
activity against the ESKAPE pathogens. MAK 9 was active against S. aureus at 50
µg/mL (125.24 µM), while MAK 12 was active against S. aureus at 200 µg/mL (696.10
µM), and MAK 11 was inactive against all six ESKAPE pathogens.
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Table 2.5. 1D NMR data for MAK 12 and pyrophen (4) in CDCl3.32
Pos

δCc

δH (m, J(Hz))a

MAK 12
1

171.3

δCb

δH (m, J(Hz))a

Pyrophen

---

169.6

---

2

20.9

1.96 (s, 3 H)

23.2

1.96 (s, 3 H)

NH

---

5.96 (d, 8.5 1H)

---

5.96 (d, 8.4, 1 H)

α

52.7

5.0 (q, 7.7, 1 H)

52.4

5.0 (dt, 7.9, 7.8, 1H)

β

38.0

3.09 (d, 7.5, 2H)

38.9

3.08 (d, 7.5 2H)

2'

162.5

---

161.3

---

3'

100.3

5.74 (d, 2.0, 1 H)

101.2

5.75 (d, 2.2, 1 H))

4'

172.0

---

170.5

---

OMe

55.5

3.75 (s, 3 H)

56.0

3.75 (s, 3 H)

5'

87.7

5.41 (d, 2.1, 1 H)

88.5

5.42 (d, 2.2, 1 H)

6'

162.9

164.4

1''

136.6

-----

135.8

-----

2''

129.0

7.12 (m, 1 H)

129.1

7.11 (br d, 6.9, 1 H)

3''

128.7

7.25 (m, 1 H)

128.7

7.27 (t, 7.5, 1 H)

4''

126.6

7.25 (m, 1 H)

127.2

7.22 (br t, 6.8, 1 H)

5''

128.7

7.25 (m, 1 H)

128.7

7.27 (t, 7.5, 1 H)

6''

129.0

7.12 (m, 1 H)

129.1

7.11 (br d, 6.9, 1 H)

a 1H

NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C
recorded at 125 MHz. c 13C shifts are taken from HMBC spectrum and multiplicity from HSQC
spetrum.

2.5.

Summary and Conclusions
Mangrove forests represent a vast source of microbial bio- and chemodiversity.

While Asian mangrove forests and their fungal endophyte communities are well-studied
chemically, the mangrove forests of Florida are virtually untapped for new, bioactive
chemistry. In order to access this potential, a HTS of mangrove endophytic fungi,
collected from throughout Florida, were screened against the six ESKAPE pathogens.
Two small molecule epigenetic modulators were utilized to activate the biosynthetic
potential of the fungal isolates in the lab.
Of the 8000 fungal extracts screened, approximately 7.5% percent were
biologically active against the EKSAPE pathogens, with an additional 20% increase in
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activity from control growth as a result of epigenetic modulation. Following the success
of the HTS, select fungal isolates were scaled up and chemically investigated for
bioactive metabolites. From a Phomasetin sp. fungus, two known cytotoxin
diastereomers, equisetin and ent-equisetin, were isolated and their structures and
bioactivity verify. From a strain of Aternaria sp., three known metabolites, altersetin,
altertoxin I, and pyrophen, were also isolated and their structures and bioactivity
verified.
The cultivation and investigation of Floridian mangrove fungal endophytes has
provided us with a large, robust library of extracts. An initial investigation of highly active
fungi yielded a number of known metabolites, indicating that earlier, more accurate
methods of dereplication are needed to more efficiently isolate new chemistry. Despite
this, the chemical potential of our extract library cannot be understated. The first round
of fungal isolates intensively studied yielded a number of bioactive metabolites, highly
diverse in their chemical structure and biological activity. As we continue to screen
these extracts in new biological assays, and develop more sophisticated dereplication
techniques, our fungal library will undoubtedly be a valuable source of new, bioactive
natural products.
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CHAPTER THREE:
MASS SPECTROMETRY BASED FUNGAL DEREPLICATION STRATEGIES

3.1.

The Need for Dereplication Strategies
3.1.1. Fungal Natural Products: The Numbers
As we enter the new age of chemical research and technology, natural products

research has never been more productive and prolific. As recently as 2016, there have
been over 260,000 natural products reported online,1 more than 50,000 of which are
marine natural products,2 with an estimated 4,000 new compounds being reported
every year.3
Fungi have played a significant role in the history of natural products chemistry:
they have provided mankind the basis for some of our most important antibiotics, like
the penicillins and cephalosporins,4 industrial chemicals, and crop and feed additives.5
Fungi are also the producers of some of nature’s most potent toxins, like the aflatoxins,
ergot alkaloids, and fusarium toxins (Figure 3.1.).6 In addition to mycotoxins, dozens of
common nuisance metabolites are known from fungi. Of the fungal genera most
commonly isolated in the laboratory (Aspergillus, Penicillium, and Fusarium), the
number of reported compounds can be well into the hundreds or even thousands (1724,
1726, and 611 compounds, respectively, listed in AntiBase).5 While new methods are
regularly developed to exploit the greater diversity of fungal chemistry (see Chapter
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Two), nuisance compounds such as the mycotoxins remain a major obstacle in the
discovery of new natural products. As this dilemma has become more prevalent, the
ability to analyze and identify known chemistry (dereplication) has become a critical
stage of microbial natural products drug discovery.

Penicillin G

Cefacetril

Aflatoxin B1

Figure 3.1. Chemical structures of penicillin G, cefacetril, and aflatoxin B1. These compounds are
representatives of the penicillin, cephalosporin, and aflatoxin compounds classes, respectively.

3.1.2. Tandem Mass Spectrometry in Metabolite Analysis
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy
are the two predominate analytical techniques employed for detecting and identifying
metabolites and small molecules. Consequently, natural product databases are built
around this spectral data, commonly combined with liquid chromatography (LC)
separation of crude extracts.7 LC-NMR databases provide powerful tools for structural
characterization of metabolites,8 which, when combined with chemotaxonomic data,9
can provide rapid identification of compound scaffolds, and identify new derivatives of a
compound class. However, NMR experiments are fundamentally more variable than
their MS counterparts, and NMR-derived database searches can very often produce an
overabundance of positive results, without accurate and certain identification of new
metabolites.7 High Resolution MS (HRMS) experiments can be faster and more
sensitive than their NMR counterparts, but the HRMS data cannot be used to
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differentiate isomeric compounds, and can similarly produce an overabundance of
identifications in a database search.8
Tandem MS (MS/MS or MS2) has emerged as an essential technique for
structural analysis of biological compounds, including peptides, proteins, and small
molecule metabolites, and has subsequently formed the basis of most dereplication
strategies employed in natural products research.10 Tandem MS involves sequential
ionization of metabolites and fragmentation of the precursor ions. The resulting
Tandem MS profile includes both the precursor ion and fragmentation pattern of each
compound.11 Ionization can occur through any number of ionization techniques
(electrospray ionization (ESI), fast atom bombardment (FAB), matrix –assisted laser
desorption/ionization (MALDI). Precursor ions within the ion source are then
fragmented, and the fragment ions are collectively detected and analyzed (Figure
3.2.).10

Figure 3.2. Diagram of Tandem MS experiment.
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Collision-induced dissociation (CID) is one such fragmentation method. An external
electrical potential is used to accelerate precursor ions so they collide with neutral
molecules (helium, nitrogen, argon), inducing fragmentation.12 CID is the mostly
commonly utilized fragmentation method in Tandem MS experiments: it is easy to
implement experimentally, the collision energy applied can be varied, resulting in a
robust fragmentation profile for each metabolite, and it is universally applicable to
biological analytes.10,12The precursor ion and fragmentation pattern is unique to each
chemical entity regardless of purity, allowing for accurate differentiation and
identification of compounds in a complex mixture.
3.1.3. Benefits and Drawbacks of Tandem MS Databases
Tandem MS provides several pieces of data that are highly useful for
characterization of secondary metabolites. The precursor ion and fragmentation pattern
of each compound is unique: a single compound can be correctly identified
independently retention time, purity, and similarity to isomeric compounds. 3 While the
Tandem MS profile for each compound is unique, compounds with similar structures will
have similar fragmentation patterns. Members of a compound class can be readily
identified from similarities in fragmentation patterns, and structural determination for
unreported derivatives can be aided by Tandem MS data (Figure 3.3.).3,5 Tandem MS
data has often been combined with other data, including chemotaxonomy,9 biological
activity, and chemical novelty13 to create versatile ad hoc databases for identification of
known compounds and new metabolites, and for prediction of the biological activity of
components in crude extracts.
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Despite the diverse and detailed public Tandem-MS databases available, there
are still obstacles to adapting them for use with private extract libraries. In a recent effort
to dereplicate ~720 microbial natural product and mycotoxins with UV/vis-MS based
methods, only 17% of the metabolite profiles overlapped with standards from common
public databases.14 This low predictive score highlights the inherent problems with
public databases: variations of experimental parameters and compound datasets can
produce inconsistent data within databases, or gaps in the data available for each
compound.3,15

Figure 3.3. Tandem MS fragmentation patterns of aflatoxin B2, G1, and M1. Different CID
energies (10mV, blue; 20mV, red; 40mV, green) result in set of fragmentation spectra unique to each
compound. Similar fragmentation patterns amongst all three are indicative of the fragmentation pattern of
all aflatoxin compounds. Spectra generated in silico Copyright: METLINTM.

Tandem-MS libraries can be especially prone to absent data, simply because TandemMS spectra are not required for compound publication. Tandem-MS profiles must be
generated independently5 or with in-silico predictive software.16 With every database,
the major limitation is that they only identify known chemistry, while new compounds
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cannot be explicitly identified. Once identified, there is often no specific methodology to
remove these nuisance compounds to more efficiently access potential new
chemistry.16 In many cases, public metabolite and mycotoxin databases are combined
with more customized databases to maximize efficiency with private extract libraries. 5,13
3.2.

Research Objectives
Fungi have been long been studied for the biologically active chemistry they

produce. Despite new chemistry being reported from fungal sources every year, fungi
remain notorious for their nuisance and toxic compounds. As fungal natural products
research evolves, early identification of these compounds has become imperative.
Many public and private spectral databases, relying heavily on Tandem MS, have been
developed to aid in the evaluation of crude extracts and to predict the presence of new
compounds. While sophisticated, many public databases can be limited in comparison
to the vast collections of fungal isolates and the nuances of individual instrumentation.
Tandem MS libraries made for specific, smaller collections of fungal compounds have
become increasingly effective for analyzing crude extracts for known chemistry.
The fungal extract library curated by the Baker lab contains thousands of fungal
extracts displaying an array of biological activity. Early efforts in our lab to study these
extracts have been hindered by the large number of mycotoxins and other nuisance
compounds, identified only after rigorous isolation efforts. In order to create an efficient
fungal natural product drug discovery program, a two-stage MS-based dereplication
strategy is herein presented. Dereplication efforts involve the creation of a Tandem-MS
fungal metabolite database to identify known chemistry in crude extracts with limited
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work up, and the development of methods to consistently and easily extract toxins from
crude extracts. Ultimately, new chemistry can be identified and more rapidly isolated.
3.3.

Dereplication Strategy Development and Validation
3.3.1. Two-Stage Dereplication and Toxin Extraction Protocol
Our fungal extract library currently contains ~8000 distinct extracts, with many

displaying biological activity against bacterial pathogens like the ESKAPE pathogens,
Mycobacterium tuberculosis, and Clostridium difficile, parasite Leishmania sp.,
amoebae Acanthamoeba sp. and Naegleria fowleri, and the Zika virus. However, most
new compound isolation has been hindered by the large number of mycotoxins present
in these fungal extracts. In order to more efficiently dereplicate these compounds and
assess other bioactive components of these extracts, a two-step protocol was
developed. The first stage involved generating Tandem-MS spectral profiles for each
bioactive crude extract and screening them against public and in-house fungal
metabolite and toxin databases, in order to identify known chemistry. Any extracts with
known or toxic compounds were then subjected to stage two, which involved a massdirected separation of the known or toxic compounds from the crude extract. The
remainder of the toxin-extracted crude extract could then be rescreened for biological
activity. This two-stage protocol would allow early identification and removal of known
and toxic compounds from a crude extract, while the rest of the metabolites could be
evaluated for biological activity and potential new chemistry (Scheme 3.1.).
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3.3.2. Creation of a Tandem-MS Database for Floridian Mangrove Endophytes
A standardized experimental protocol utilizing a high resolution Liquid
Chromatography/ Quadrupole-Time of Flight mass spectrometer (LC/Q-ToF/MS) was
established for application with all crude fungal extracts.

Scheme 3.1. Metabolite dereplication protocol for crude fungal extracts. Spectrometer images
courtesy of AgilentTM, https://www.agilent.com

This protocol was specifically designed to minimize preparative steps of the crude
extract, and allow manual assessment of the crude extract. A test set of fungal extracts
containing known, previously isolated mycotoxins (KML14-75MG-C8, containing
equisetin and ent-equisetin; HF14-17C-3B, containing altersetin, altertoxin I, and
pyrophen) was used to generate and verify this protocol (Figure 3.4.). These extracts
and metabolites displayed potent biological activity against Staphylococcus aureus, one
of the six bacterial ESKAPE pathogens.
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Equisetin

Ent-equisetin

Altersetin

Altertoxin I
Pyrophen
Figure 3.4. Chemical structures of equisetin, ent-equisetin, altersetin, altertoxin I, and pyrophen.
These compounds were used to validate the LC-MS/MS protocols and databases developed.

Liquid Chromatography MS (LC-MS) and Liquid Chromatography Tandem-MS
(LC-MS/MS) spectral profiles were generated for each crude extract. In order to remove
hydrophobic metabolites incompatible with LC-MS/MS solvent system, test extracts
were partitioned between hexanes and 1:3 H2O:MeOH . Comparison of nonpartitioned
and partitioned extracts indicated a higher yield of hydrophilic metabolites that could be
evaluated by LC-MS/MS after removal of hydrophobic components. However, both
partitioned and non-partitioned extracts had the same metabolite profile (Figure 3.5.).
Extracts were subjected to LC-MS with a standardized elution gradient to generate a
metabolite chromatographic profile. Crude extracts were then subjected to Automatic
LC-MS/MS experiments. The Automatic LC-MS/MS experimental protocol utilized the
same standardized elution gradient as the LC-MS experiment, with CID energies of
0mV, 10mV, and 40mV selected to match data provided in most public databases.
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Figure 3.5. Comparative LC-MS Chromatograms of HF14-17C-3B crude extract and partitions.
The 1:3 H2O:MeOH partition (“MeOH Part.) contained a higher yield of metabolites than the nonpartitioned crude extract (“Crude”).

LC-MS and LC-MS/MS chromatograms were evaluated with AgilentTM Qualitative
Analysis software. Automated compound identification protocols were used to identify
distinct metabolites in each LC-MS/MS experiment and to group fragmentation profiles
for each metabolite; retention time (RT) and HRMS were verified with the LC-MS
chromatogram for each extract (Figure 3.6.). Two public accurate mass LC-MS/MS
databases, METLIN-AMRT-PCDL and Mycotoxins-AMRT-PCDL, were utilized to
identify metabolites. Our protocol was verified with equisetin and ent-equisetin, which
were both correctly identified in crude extracts with the Mycotoxin-AMRT-PCDL.
However, other compounds (altersetin, altertoxin I, and pyrophen) were not identified in
the crude extract by any of the public databases, as Tandem-MS profiles for those
metabolites have not been previously reported or generated in silico. While public
databases provide an accurate first tier of dereplication, we sought to develop an inhouse database specific to our fungal extracts to complement the existing public
databases.
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Figure 3.6. Mass Spectroscopic profile of equisetin. (A) HRESIMS profile of equisetin extracted
from (B) the LC-MS chromatogram of crude KML14-75MG-C8, (C) with automatic MS/MS
fragmentation pattern at 0mV, 10mV and 40mV (C).

3.3.3. Baker Lab Fungal Metabolite Database
A Tandem-MS Baker Lab Fungal Metabolite Database was constructed using
Agilent Personal Compound Database and Library (PCDL) software. Of the pure
compounds isolated from our lab, 45 new and known compounds have been isolated
from both Floridian and Asian mangrove endophyte fungi. Each compound entry within
the PCDL contains the HRESIMS, Tandem MS fragmentation profile, and chemical
structure generated from IUPAC International Chemical Identifier (InChI). The Baker
Lab Fungal Metabolite Database was verified with the test extracts KML14-75MG-C8
and HF14-17C-3B. In both extracts, all known compounds were identified in the Baker
Lab Fungal Metabolite Database. A second round of verification was performed on a
separate extract (HF14-52C-2A), which was grown independently of the test extracts
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and also contained equisetin. Equisetin was identified from the Tandem MS profile of
the crude extract using the Baker Lab Fungal Metabolite Database.
3.3.4. Mass-Guided Toxin Extraction
The second stage of the dereplication protocol is the extraction of known and
toxic metabolites once they were identified in crude extracts. In order to develop an
extraction protocol, KML14-75MG-C8 was used as a test crude extract, with equisetin
and ent-equisetin as toxins being targeted for extraction.
Extraction of toxins and known compounds was directed by the LC-MS profile of
the crude extracts. Following identification of nuisance compounds, the crude extract
was subjected to preparative Reverse Phase (RP) HPLC using H2O and MeOH. As with
the LC-MS and MS/MS experiments, a standard elution gradient was utilized to
maximize separation of components in the crude extract, while also retaining time
efficiency. Fractions were collected based on 220nm UV absorption (Figure 3.7.).

Figure 3.7. RP HPLC Chromatogram of KML14-75MG-C8 with elution gradient (blue) and 220nm
UV trace (black). Fraction collection (red) is labeled, with fraction 10 containing equisetin and entequisetin.
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The separated fractions were individually subjected to LC-MS analysis, and the
fraction containing equisetin and ent-equisetin (fraction 10) were identified by
HRESIMS. The remaining fractions were recombined, and, along with the crude extract
and the fraction containing the extracted equisetin were screened against S. aureus. As
indicated in Table 3.1., the crude extract was biologically active against S. aureus
(MIC= 100μg/mL), as was the fraction containing the extracted toxins (MIC= 50μg/mL).
However, the remaining extract was inactive against S. aureus, indicating that the
biological activity against S. aureus can be attributed to the toxins, with no other
metabolites displaying significant activity.
Table 3.1. Biological Activity of KML14-75MG-C8 fractions against Staphylococcus aureus before
and after toxin extraction
Extract

MIC (μg/mL)

KML14 Crude

100

KML14 Crude (Toxin
Extracted)
Extracted equisetin

Inactive
50

The two stages of our dereplication strategy are aimed at identifying and
extracting known and toxic compounds from our fungi. As a full illustrative example,
KML14-75MG-C8 was subjected to LC-MS and LC-MS/MS experiments, and both
equisetin and ent-equisetin were identified in the crude extract from their Tandem MS
profiles by both our private and public databases. Following identification of these
mycotoxins, a mass-directed HPLC extraction of equisetin and ent-equisetin was
performed, and the remaining extract was rescreened for biological activity against S.
aureus. With no activity in the toxin-extracted extract, this crude extract can be
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successfully deprioritized as a source of potential new, bioactive chemistry with
relatively little chromatographic separation.
3.4.

Proof of Concept: Isolation of a New Natural Product
Following the creation of the Tandem-MS database, several fungal extracts were

evaluated for their potential bioactive chemistry. One fungal isolate, HF14-37B-1B, was
isolated from mangrove tissue in the Tampa Bay area. Initial screening of the isolated in
DNMTi modified growth conditions displayed biological activity against Staphylococcus
aureus, and the fungus was subsequently grown in large scale and extracted. Though
the crude extract displayed no biological activity, the extract was subjected to Normal
Phase (NP) Medium Pressure Liquid Chromatography (MPLC), and several of the
resulting fractions displayed biological activity. One fraction, H, displayed biological
activity to 50μg/mL. However the low mass of the fraction resulted in it being rejected for
further analysis in favor of other fractions.
The HRESIMS of HF14-37B-1B-H indicated once major component, with a large
number of minor contaminants. The Tandem MS profile for the fraction was evaluated in
both the Baker Lab Fungal Metabolite Database, and METLIN-AMRT-PCDL and
Mycotoxins-AMRT-PCDL databases: in all searches, there were no matches for the
major component in the fraction. Following our dereplication and prioritization protocol,
the extract was selected for further study. The fraction was subjected to reverse phase
(RP) High Performance Liquid Chromatography (HPLC) with H2O and ACN, leading to
the purification of compound 1 (Scheme 3.2.).
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Compound 1 was determined to have a molecular formula of C10H9NO3 based on
HRESIMS (m/z 192.0666 [M+H]+). Evaluation of the 1H and 13C NMR spectra indicated
the presence of a 1,2-disubstituted benzene ring, two carbonyls, and a deshielded
methyl and methine (Table 3.2).

Scheme 3.2. Isolation of MAK 12

2D NMR spectra (gCOSY, gHMBC) were used to determine the structure of 1.
gCOSY correlations between positions 6-9 verified the 1,2-disubstituted aromatic ring,
and the spin system comprising positions 3 and 10. The carbon shift of positions 5 (δ C
172.2) and 5a (δC 122.0) and gHMBC correlations between positions 5 and 6 indicated
that position 5 was a benzylic ester carbonyl. Similarly, the shift of position 9a (δ C 138.7)
indicated a benzylic amine or amide. The chemical shifts of positions 3 (δ C 68.8) and 10
(δC 20.1), and gHMBC correlations between positions 10 and 2 (δC 175.5) supported
their linking the benzylic ester and benzylic amide, providing the completed structure of
1 (Figure 3.9.). Position 3 represents the only stereocenter in 1. Stereochemistry was

68

determined by optical rotation and comparison to synthetic derivatives of 1 with known
absolute stereochemistry.17 The specific rotation of 1 ([𝛼]25
𝐷 = -37.0) indicated an Sconfirmation of position 3. Compound 1 was biologically active against S. aureus at
50μg/mL (261.72 µM).
Table 3.2. 1D NMR data for 1in MeOH-d4.
Pos

δCb

δH (m, J(Hz))a

2

175.7

---

3

68.8

4.20 (q, 6.8, 1 H)

5

172.2

---

5a

122

6

128.4

--7.70 (dd, 7.7, 1.4.,
1 H)

7

123.5

7.14 (m, 1 H)

8

132.7

9

121.5

7.47 (m, 1 H)
8.50 (dd, 8.0, 1.0, 1
H)

9a

138.7

---

10

20.1

1.40 (d, 6.8, 3 H)

Figure 3.8. Structure of compound 1. Important
gCOSY (bold) and gHMBC (arrow) correlations
are shown.

a 1H

NMR recorded at 500 MHz, reported in ppm
(multiplicity, J-coupling (in Hz), integration); b 13C
shifts are taken from HMBC spectrum and
multiplicity is taken from HSQC spectrum.

The isolation and identification of 1 is significant for several reasons.
Interestingly, though it is a new natural product, compound 1 has been reported as an
intermediate in the synthesis of various 4-quinazolinones in 1963.18 The original
synthesis was undertaken to produce natural product mimics, as 4-quinazolinones were
determined to be important structural components to plant alkaloids.18 Importantly, 1
represents a new compound that was isolated in accordance with our two-stage
dereplication strategy, in a fraction that would otherwise have been deprioritized due to
low mass. It serves as a verification that our dereplication strategies can be used to
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evaluate the metabolite profile of extracts quickly, and aid in identifying and isolating
new, bioactive natural products
3.5.

Summary and Conclusions
The ability to identify known and toxic compounds early has become critical in

microbial natural products drug discovery. Every year, thousands of new compounds
are reported in the literature, adding to the already impressive number of bioactive
secondary metabolites derived from fungi and other microbes. Numerous strategies
utilize NMR, Tandem MS, and structural databases in order to identify known chemistry
and prioritize new compound isolation. Many public Tandem MS databases exist with
experimental and in silico fragmentation patterns for a wide array of fungal metabolites,
and private databases tailored to specific fungal libraries can be highly effective in
identifying known and toxic compounds.
Our fungal library contains thousands of extracts with a range of biological
activity. However, chemical investigation efforts have been hindered by repeated
isolation of toxins and known compounds. We developed a two-stage mass
spectrometry based dereplication strategy in order to identify these nuisance
compounds in crude extracts, remove them, and assess the remaining metabolites.
Standardized Tandem MS experiments were used to build a private database of fungal
metabolites isolated in our lab, which was used to successfully identify toxins from
crude extracts without any chromatographic separation. In order to extract these toxins,
a standardized HPLC experiment, guided by HRESIMS profiles of crude extract, was
used to successfully extract the toxins, while the rest of the extract could be tested for
biological activity.
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Finally, our dereplication strategies were validated as a tool to aid in the
discovery of new, bioactive compounds. A fungal extract, previously deprioritized due to
low mass, was evaluated in our two-stage dereplication protocol. The extract had no
known metabolites identified in our databases, and a new, bioactive benzoxazepine was
subsequently isolated. The discovery of this compound demonstrates the importance of
dereplication strategies and the efficiency with which they can be used to discover new
natural products.
3.6.
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CHAPTER FOUR:
FRIOMARAMIDE: NEW PENTAPEPTIDE ISOLATED FROM ANTARCTIC SPONGES

4.1.

The Impact of Marine Natural Products
4.1.1. The Chemical and Biological Diversity of the World’s Oceans
The world’s oceans, covering ~70% of the Earth’s surface, represent the largest

source of biological and chemical diversity on the planet.1 This is especially true of
animal biodiversity. Of the reported animal phyla, only one is exclusively terrestrial,
while 15 phyla occur exclusively in marine environments.2 Of the marine-dwelling
animals, invertebrates are the most taxonomically diverse, including phyla like Porifera,
Cnidaria, Annelida, Arthropoda, Mollusca, and Echinodermata (Figure 4.1.), and
together represent 60% of marine animals.3,4 Many of these invertebrates are sessile
and soft-bodied, and so must rely on potent chemical defenses to deter predators, 1
making them promising sources of unique, bioactive chemistry.

Figure 4.1. Marine invertebrates. From left: Staghorn Coral (Acropora cervicornis) of the phylum
Cnideria (Photo by Albert Kok, Dutch Wikipedia), red encrusting sponge (Monanchora arbuscular)
of the phylum Porifera (Photo by Nick Hobgood), and Crown of Thorns starfish (Acanthaster
planci) of the phylum Echinodermata (Photo by Jon Hanson).
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Over the last half-century, marine sources have become a promising source of
new, bioactive chemistry. Some of the earliest research in marine natural products
began in the 1950s, alongside advancements in taxonomic and sampling studies for
marine organisms.5 In the following three decades, the field of marine natural products
became more productive and economic, until, in the late 1980s and 1990s, marine
natural products became a prevalent and prolific source of new natural products. 6 From
1990-2005, approximately 8000 new marine natural products were reported in the
literature, with almost 70% reported from marine invertebrates.4

Figure 4.2. Trend in the occurrence of natural product scaffolds. Most novel natural product
scaffolds occur very few times throughout marine natural product chemistry.7

The chemistry of marine invertebrates has been shown to be both more novel
and have more significant and relevant biological activity than terrestrial natural
products.8 In a comparative analysis of marine and terrestrial natural product scaffolds
reported in Dictionary of Natural Products (version 17:2) and Dictionary of Marine
Natural Products (2007.6), more than 70% of marine natural product scaffolds were
exclusively utilized by marine organisms, while terrestrial natural product scaffolds had
significantly less exclusivity. Of the ~4000 marine natural product scaffolds, only a few
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are prevalent throughout marine natural products, with more than half of the scaffolds
occurring in only one incidence within reported marine natural products (Figure 4.2.).7
In a National Cancer Institute preclinical cytotoxicity screen, more than 1% of marine
derived samples displayed anti-tumor potential, compared to less than 0.5% of
terrestrial samples screened (Figure 4.3.).9

Figure 4.3. Distribution of samples with significant cytotoxicity in a per-clinical screening by the
NCI. Raw number of active samples shown in italics.9

Terrestrial natural products represent the bulk of natural product-related
marketed drugs.8 However, marine-sourced drugs are quickly becoming relevant in the
clinical pipeline. Five marine-source drugs are currently reported on the market:
cytarabine (Ara-C, Cytosar-U®) and vidarabine (Ara-A, Vira-A®), synthetic sponge
natural product mimics approved as anti-cancer and anti-viral drugs, respectively,
ziconotide (Prialt®), a synthetic equivalent to a cone snail derived peptide, approved to
treat severe chronic pain, trabectedin (Yondelis®), an anti-cancer drug first isolated
from a marine tunicate, and eribulin mesylate (HalavinTM), a sponge natural product
derivative most recently approved to treat breast cancer (Figure 4.4.).8 In addition to
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marketed drugs, there are many marine-related lead compounds in various stages of
the clinical pipeline, addressing disease areas like cancer, pain managements,
Alzheimer’s disease, wound healing, and anti-inflammation.1 As more novel chemistry is
reported, marine natural products will continue to play a critical role in the development
of new marketed drugs for a variety of disease targets.

Cytarabine, Ara-C

Vidrabine, Ara-A

Eribulin Mesylate

Trabectedin

Ziconotide

Figure 4.4. Chemical structures of marine natural product-related compounds that have been
approved as marketed drugs.

4.1.2. Cold Water Oceans: Hotbeds of Chemical Discovery
Despite the large body of research in the marine environment, most marine
natural products have been isolated from tropical or temperate waters. For obvious
reasons of sampling, climate, and accessibility, cold water organisms are significantly
less studied than their warm water counterparts.10 Of new marine natural products
reported from 1990-2010, over 60% were reported from organisms collected at or north
of the equator, with tropical organisms accounting for 51% of new marine natural
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products.4 As marine natural products interest has intensified, research in the polar
regions has expanded rapidly, leading to new interest in cold water ecosystems for
chemical diversity.4

Figure 4.5. The Antarctic Circumpolar Current (ACC). (a) The geographical area and direction of
the ACC, and (b) the surface speed from a high resolution numerical model. Copyright Anthony
Thompson, Caltech, http://web.gps.caltech.edu/~andrewt/research/acc.html, 2018.

The cold water Southern Oceans surrounding Antarctica are some of the largest
in the world, comprising 10% of total world ocean area.11 Antarctica’s geographic and
biological isolation is largely attributed to the Antarctic Circumpolar Current (ACC).
Though relatively slow, it is the largest ocean current in the world and circulates
clockwise around the continent,11 transporting nutrient rich deep water throughout the
waters surrounding Antarctica while isolating it from northern oceans (Figure 4.5.).12
Antarctica has a highly productive marine ecosystem.13 The benthic waters are
dominated by large macroalgal forests and rich assemblages of sponges, soft corals,
bryozoans, hydroids, and ascidians.12 Many of these soft-bodied invertebrates
experience intense predation, so the chemical diversity of Antarctic marine invertebrates
is high.10
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Antarctic invertebrates have provided numerous unique and bioactive natural
products (Figure 4.6.). The meridianins and palmerolide A, both isolated from Antarctic
tunicates, exhibit biological activity in cancer-related assays.10 Many of the meridianins
prevent cell proliferation and encourage cell apoptosis,14 while palmerolide A has
extremely potent and selective melanoma cell line activity.15 The shagenes, isolated
from an unidentified Antarctic octocoral, are tricyclic sesquiterpenes. Shagene A
exhibits notable activity against the infected macrophage stage of the Leishmania
donovani parasite, with no cytotoxicity to the mammalian host cell.16 The red alga,
Plocamium cartilagineum, has been extensively studied ecologically, and has been
found to produce new polyhalogenated monoterpenes like anverene. 10 Anverene
displays an inhibitory effect on vancomycin-resistant Enterococci faecium (VRE).17 The
vast biological and chemical diversity in the Southern Oceans surrounding Antarctica
make it a promising source of new natural products.

Meridianin A

Palmerolide A

Shagene A

Anverene

Figure 4.6. New, biologically active natural products isolated from Antarctic invertebrates.
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4.1.3. Porifera as Sources of Unique Natural Products
Sponges of the phylum Porifera are among the most well-known and well-studied
marine invertebrates. Sponges are morphologically and taxonomically diverse, are
widespread in the world’s oceans, and play important ecological roles in benthic
waters.18 Chemically, sponges predominate natural products drug discovery. Of all
marine invertebrate natural products reported from 1990-2010, nearly half were
reported from phylum Porifera, with approximately 250 new natural products reported
on average every year.4 In the last ten years, more new sponge natural products (~2500
total) have been reported than any other marine invertebrate phyla (Figure 4.7.).19
Sponges, being soft-bodied and sessile organisms, produce a variety of chemical
defense to deter predators, prevent fouling, and to cultivate their extensive symbiotic
microorganisms.20,21

Figure 4.7. Number of new compounds reported per phyla from 2001-2010.19

The natural products isolated from sponges are known for their chemical novelty
and potent, broad biological activity.19 New natural products from sponges have been
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reported to be active in many different disease areas, including anti-fungal,
immunosuppressive, cancer cell lines, and as antibiotics.19,22 Both cytarabine and
vidrabine, FDA approved drugs, are derived from metabolites of Caribbean sponge
Tethys crypta.8,23 In addition to marketed drugs, there are sponge metabolites
throughout the clinical pipeline: Zalypsis®, a phase II anti-tumor agent, is derived from
renieramycin isolated from Netropsia sp.,23 IPL512602, a phase II anti-inflammatory
asthma control agent, is a synthetic derivative of a steroid isolated from Petrosia
contignata,1 and PM050489 and PM060184, phase I chlorinated polyketides with
antimitotic activity, were isolated from Lithoplocamia lithistoides.23
While most reported sponge chemistry is from tropical or temperate climates,
sponges from polar regions, and Antarctica specifically, have produced unique new
chemistry (Figure 4.8.). The discorhabdin alkaloids are a widespread and important
class of compounds found in Lactrunculiidae family of sponges found in the southern
oceans.10 In addition to acting as feeding deterrents for the producing sponges,24 many
discorhabdins, like discorhabdin R, display activity against select Gram-positive
(Staphylococcus aureus, Micrococcus luteus) and Gram-negative (Serratia
marcenscens, Escherichia coli) bacteria.10 Membranolides C and D, natural product
artefacts isolated from Antarctic sponge Dendrilla membranosa, are active against
Gram-negative bacteria and fungi, as well as tropical parasite Leishmania donavani.10
Caminatal, an aldehyde sesterterpene, was isolated from Suberites caminatus. Though
lacking biological activity, caminatal, and its related compounds, represent novel
molecular scaffolds reported from Antarctic sponges.10,25
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Discorhabdin R

Membranolide C

Caminital

Figure 4.8. Chemical structures of Antarctic sponge metabolites discorhabdin R, membranolide
C, and caminatal.

4.2.

Research Objectives
The ocean contains the largest source of animal biodiversity on the planet. Of the

many animal phyla that inhabit the oceans, marine invertebrates, often soft-bodied and
sessile, produce an abundance of biologically active natural products to serve as a
chemical defense. Marine natural products have been, and continue to be, an
invaluable source of unique, novel, and bioactivity chemistry. Despite the vast size and
biological diversity of the world’s cold oceans, marine natural products are
predominated by research in tropical and temperate climates. The cold water oceans
surrounding Antarctica represent a largely untapped chemodiversity source.
In an effort to explore the full potential of marine Antarctic invertebrates, the
Baker lab has made efforts to study a variety of Antarctic invertebrates, in particular
sponges, for new chemistry. Herein is presented the study of a collection of unidentified
Antarctic sponges for new, bioactive natural products.
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4.3.

Isolation and Characterization of Friomaramide
4.3.1. Collection, Extraction, and Compound Isolation
A collection of sponges, collectively documented as NBP13-24, were collected by

trawling in the Scotia Arc on the Nathanial B. Palmer research vessel. The sponges had
many morphological similarities, though a taxonomic identification was not possible
(Figure 4.9.). The sponges were initially handled and extracted individually: each
sponge was extracted for two 24 hr periods in 1:1 DCM:MeOH, followed by a 24hr
extraction in 1:1 H2O:MeOH. The individual extracts were subjected to analysis with
Liquid Chromatography Mass Spectrometry (LC-MS) in order to compare the chemical
extracts. Of the eight collected sponges, seven of them had identical metabolite profiles;
the similar extracts were combined together for analysis.

Figure 4.9. Voucher photos of the eight sponges identified as NBP13-24. Photo by Bill J. Baker.

The crude extract was subjected to Normal Phase (NP) Medium Pressure Liquid
Chromatography (MPLC) with a hexane and EtOAc gradient with a 1:3 MeOH:EtOAc
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wash. Of the fractions collected, none displayed biological activity. However, fraction E
was prioritized for analysis based on the fraction’s mass and 1H NMR spectrum.
Fraction E was subjected to iterative rounds of separation with reversed phase (RP)
HPLC using H2O and MeOH. Following purification with RP HPLC with H2O and ACN,
compound 1 was isolated (Scheme 4.1).

Scheme 4.1. Isolation of compound 1.

4.3.2. Structure Elucidation of Friomaramide
Compound 1 was determined to have a molecular formula of C46H67N7O6 based
on HRESIMS (m/z 814. 5243 [M+H]+, calculated 814.5231). Evaluation of the 1H and
13C

NMR spectra (Table 4.1.) indicated that compound 1 contained several nitrogen-

bearing methyl groups, multiple aromatic rings, and multiple carbonyls. 2D NMR
techniques (gCOSY, gHMBC) were utilized to determine the structure of the molecule
(Figure 4.10.). gHMBC data correlated each methine proton (δH 5.00-5.50) to two
carbonyls (δC 173.0-173.5) and a single amide methyl (δH 2.75-3.10). These
correlations suggested that the molecule was a linear peptide, with each α-position
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methine displaying long-range correlations to the carbonyl of its own amino acid, and of
the subsequent amino acid in the chain. Interestingly, all of the amino acids displayed
nitrogen methylation, indicated by the number of and gHMBC correlations of the amide
methyl groups. With this knowledge, gCOSY correlations were used to construct each
amino acid within the molecule. An alanine, phenylalanine, valine, and two isoleucine
residues were thus identified.

Friomaramide

Figure 4.10. Chemical structure of 1. Important gCOSY (bold) and gHMBC (arrows) correlations
are shown.

The sequence of these five methylated amino acids was established using
gHMBC correlations, supported by analysis of the ESIMS fragmentation pattern. In
particular, the α-position methine protons, which displayed correlations to the adjacent
amide carbonyls, were critical to establishing the peptide sequence. The α-position
methine of Phe (δH 5.14) displayed a gHMBC correlation to its own amide carbonyl (δC
172.4), but no other amino acid carbonyls, indicating it was a terminal amino acid. The
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α-position methine of Val (δH 5.34) displayed correlations to both its own carbonyl (δC
170.3) and Phe carbonyl; the α-position methine of Ala displayed correlations to its own
carbonyl (δC 173.3) and the Val carbonyl; the α-position methine of Ile-1 (δH 5.09)
displayed correlations to its own carbonyl (δC 170.4) and the Ala carbonyl; the α-position
methine of Ile-2 (δH 5.34) displayed correlations to its own carbonyl (δC 170.8) and the
Ile-1 carbonyl, with Ile-2 terminating the amino acid sequence. The sequence of PheAla-Val-Ile-Ile was thus established. The N-terminus of the peptide was determined to
be acetylated, indicated by gHMBC correlations between the acetyl methyl group (δH
1.92) and the α-position methine of Phe (δH 5.14), and the acetyl carbonyl (δC 171.5).
The C-terminus was composed of a decarboxylated tryptophan residue, tryptenamine.
gCOSY and gHMBC correlations were used to establish the structure of the tryptamine.
Though no long-range correlations existed between this residue and the rest of the
peptide, the ESIMS fragmentation verified its placement in the peptide, completing the
structure of 1.
The sequence of the amino acids was verified independently from the
ESIMS fragmentation pattern (Figure 4.11.) utilizing Protein ProspectorTM software.
When provided with major ESIMS mass fragments, the software verified the sequence
of amino acids of 1 to be Ac-Me Phe-Me Ala-Me Val-Me Ile-Me Ile, with the remainder
of the structure attributed to the tryptophan residue. This allowed verification of the
structure of 1.
Stereochemical analysis of 1 performed with Marfey’s analysis as described in
the literature.26,27 Briefly, 1 was hydrolyzed to the individual amino acids, which were
then derivatized with the chiral Marfey’s reagent, FDAA (Nα-(2,4-dinitro-5-flourophenyl86

L-alaninamide),

which allowed the amino acid enantiomers to be distinguishable from

one another chromatographically. These reaction products were evaluated using a
routine LC-MS experiment, and, by comparison to similarly derivatized amino acid
standards, the configuration of each amino acid in 1 could be determined. The absolute
configuration of 1 was determined to be D-Phe-L-Val-L-Ala-L-Ile-L-Ile (Figure 4.11.).

Figure 4.11. ESIMS fragmentation pattern of 1.

4.3.3. Biological and Chemical Importance
Friomaramide (1) is a pentapeptide with full nitrogen methylation of the amino
acids. Peptides are typically biosynthesized by non-ribosomal peptide synthases
(NRPS), which can insert a multitude of post-translational modification into the
synthesized peptides. Nitrogen methylation is one such modification to individual amino
acids as they are added to the growing peptide.28 Peptide methylation is attractive in
drug discovery, as non-methylated peptides have poor pharmacokinetic properties
(short in vivo half-life, poor oral availability) that can be improved by methylation.29
Though uncommon, naturally occurring single or multiple N-methylated peptides have
been reported from marine and terrestrial sources.26,30–34
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Table 4.1. 1D NMR data for friomaramide (1) in MeOH-d4 .
Pos

δCb

δH (m, J(Hz))a

CO

171.3

---

-Me
Phe

24.1

1.92 (s, 3 H)

CO

172.4

---

α

53.0

5.14 (t, 15.7, 1 H)

β

40.2

2.90 (m, 1 H)

Ac

3.05 (m, 1 H)
1

136.9

---

2/6

129.5

7.28 (br m, 2 H)

3/5

129.0

7.25 (br m, 2 H)

4

130.0

7.23 (br m, 1 H)

32.1

2.86 (s, 3 H)

CO

170.3

---

α

60.4

5.34 (d, 10.9, 1 H)

β

29.9

2.21 (m, 1 H)

γ

20.8

0.80 (d, 7.3, 3 H)

γ'

18.7

0.83 (d, 7.3, 3 H)

32.7

2.78 (s, 3 H)

N-Me
Val

N-Me
Ala
CO

173.3

---

α

53.3

5.17 (m, 1 H)

β

16.8

1.20 (d, 7.0, 3 H)

32.1

2.95 (s, 3 H)

CO

170.4

---

α

59.3

5.09 (d, 11.0, 1 H)

β

24.1

1.98 (m, 1 H)

β-Me

19.0

0.76 (d, 6.5, 3 H)

γ

31.8

1.29 (m, 2 H)

δ

17.1

0.60 (d, 6.5, 3 H)

N-Me

32.7

3.01 (s, 3 H)

N-Me
Ile-1

a 1H

NMR recorded at 800 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C
NMR recorded at 200 MHz.
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Table 4.1. (Continued) 1D NMR data for friomaramide (1) in MeOH-d4 .
Pos

δCb

δH (m, J(Hz))a

CO

170.8

---

α

60.4

5.14 (m, 1 H)

β

35.8

2.10 9m, 1 H)

β-Me

20.0

0.81 (d, 6.5, 3 H)

Ile-2

γ

29.4

1.32 (m, 2 H)

δ

19.3

0.76 (d, 6.5, 3 H)

N-Me
Tryptenamine

35.0

3.09 (s, 3 H)

2

128.1

7.22 (s, 1 H)

3

109.8

---

3a

126.7

---

4

118.1

7.60 (d, 7.8, 1 H)

5

122.0

7.08 (t, 7.2, 1 H)

6

125.4

7.15 (t, 7.2, 1 H)

7

111.1

7.36 (d, 7.8, 1 H)

7a

136.8

---

α

121.6

6.59 (d, 8.2, 1 H)

β

125.9

6.31 (d, 8.3, 1 H)

a 1H

NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C
NMR recorded at 200 MHz.

Interestingly, both terrestrial32 and warm water marine derived33,34 Aspergillus spp. have
been reported to produced highly methylated peptides with an acetylated N-terminus,
and a tryptenamine C-terminus, similar to friomaramide. It is not uncommon for primary
production of natural products to be carried out by host-associated fungi.10,31 Given the
structural similarities of friomaramide to marine fungal peptides, primary production may
be carried out by fungi associated with the collected sponges, rather than the sponges
themselves.
Of reported N-methylated peptides, the vast majority are only highly methylated.
Full nitrogen methylation of the amino acids is exceptionally rare, with only a single
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class of compounds, isolated from tropical brown cyanobacteria Lyngbya majuscula,
reported in the literature.26 Friomaramide is, to the best of our knowledge, the only other
fully methylated natural product peptide, the first isolated from a cold water organism,
and the first isolated from a non-cyanobacterial organism.
4.4.

Summary and Conclusions
The cold water oceans surrounding Antarctica contain vast biological and

chemical diversity. Despite this, the study of marine invertebrate chemistry has lagged
behind research efforts in tropical and temperate water oceans. Given the unique and
bioactive natural products reported from such cold water invertebrates, our lab seeks to
tap the vast potential for new lead compounds.
A collection of unidentified sponges were collected in the Scotia Arc of the
Southern Ocean. After extraction, chemically similar sponges were combined and
subjected to chemical investigation. From the collection of sponges, a new compound,
friomaramide (compound 1) was isolated, and its structure elucidated using NMR and
MS techniques. Friomaramide is a pentapeptide, and is the first naturally occurring
peptide displaying full nitrogen methylation.
4.5.
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APPENDIX A:
EXPERIMENTAL AND SUPPORTING DATA FOR CHAPTER TWO
Microbial Isolation Protocol
Screening Protocol
Microbial Scale Up Protocol
Chromatographic Isolation Protocol
Compound Data
Microbial Isolation Protocol
Solid media was made from a variety of nutrient components (sabouraud
dextrose broth (SDB), potato dextrose broth (PDB), trypticase soy broth/agar (TSA),
Actinomycete Isolation Agar, Malt Extract Agar) and agar produced by DB TM DifcoTM,
and, along with FisherbrandTM petri dishes, were purchased through Fisher Scientific.
Glycerol, chloramphenicol, cycloheximide, and nystatin were purchased from Sigma
Aldrich®.
Media components were mixed according to manufacturer’s instructions, heated,
autoclaved, and set in petri dishes.
Mangrove tissue was collected from the bark, stem, roots, and leaves of the tree.
Tissue was surfaced sterilized in IPA, cut into 1 cm3 pieces, and embedded in four
locations on each agar plate per media type. Field plates were incubated at 20-25 oC
(room temperature) for 1-4 weeks, or until all fungal isolates had been harvested or the
plate had become overgrown with fungal growth. Small, 1 cm 3 pieces of fungal isolates
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harvested from the field plate were transferred to a new plate of the same media plate,
and incubated at 28 oC. Transfer and isolation procedure was repeated until a single
fungal culture was isolated onto a plate, at which point the isolate was transfer to an
untreated SDB agar plate. Upon growth on the SDB plate, 10-12 1cm3 pieces were
stored in a cryotube in 20% glycerol for long term storage. Descriptions of each fungal
isolate were recorded.
Screening Protocol
Epigenetic modulators sodium butyrate (HDACi) and 5-azacytidine (DNMTi) were
purchased from Sigma Aldrich®. Modifiers were introduced as a 100 µM solution of
each modifier in SDB, stored in 1.25 mL EppendorfTM microcentrifuge tubes purchased
from Fisher Scientific. Rice media was made by autoclaving 1 g of unbleached and
untreated brown rice, purchase from HoneyVille FarmsTM, in 3 mL of DI water in a 20
mL scintillation vial. CorningTM 96-well 200 µL clear polypropylene microplates and
FisherbrandTM 96-well DeepWellTM polypropylene microplates were purchased from
Fisher Scientific.
Each fungal isolate was grown on an SDB agar plate. Once a colony was
established, three 1 cm3 pieces were transferred into 1.25 mL each of untreated SDB,
HDACi treated SDB, and DNMTi treated SDB in a sterilized microcentrifuge tube. Each
mixture was agitated and poured over a vial of rice media. Once inoculated with fungal
culture, each vial was incubated for 21 days at 28 oC. Following incubation, fungal
colonies were inspected for growth and contamination. Fungal samples that had not
grown to a sufficient size (covering approximately half the rice media) were incubated
for another 7 days and reevaluated; fungal colonies that displayed bacterial or multiple
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fungal growths were discarded. Fungal colonies that were to be extracted were first
doused with MeOH to dampen the surface of the fungal mat, after which 10 mL of
EtOAc was added to each vial, and the rice and fungal colony were broken apart with a
metal spatula and suspended in the EtOAc to extract overnight. After approximately 24
hrs of extraction, the supernatant of each vial was transferred into a clean, pre weighed
vial, while the solid rice and fungal colony were discarded. The collected extract was
dried down and weighed, and redissolved to 5 mg/mL in DMSO. From each extract, five
duplicate plates were made with 150 µL/well in CorningTM polypropylene microplates to
be sent for bioassay. Of the remaining extract, duplicate FisherbrandTM DeepWellTM
polypropylene plates were made each with 2 mL/well for long term storage of extracts.
Microbial Scale Up Protocol
Scaled up growth protocols for fungal cultures were developed to mirror the small
scale HTS growth protocol, and were followed for all scaled up fungi. In a Type 3T
Unicorn bag, 300 g of rice and 500 mL of dionized water were mixed, and the bag heat
sealed and autoclaved. Fungi selected for scale up were regrown on a SDB agar plate.
Several 1 cm3 pieces of the fungal colony were transferred into triplicate Fisherbrand TM
50 mL Falcon Tubes, each containing 50 mL each of untreated SDB, 100 µL HDACi
SDB solution, or 100 µL DNMTi SDB solution. Each set of falcon tubes were agitated
and poured over the rice, and the rice physically agitated to mix the rice, SDB solution,
and fungal cubes. Bags were taped closed, and incubated at 28 oC for 21 days. After
the incubation period, a cotton swab was used to piece the fungal colony, and was
swabbed on an SDB agar plate to check for bacterial contamination or multiple fungal
growths in the bag. The top of the fungal mat was dowsed in MeOH, and the rice and
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fungi broken apart and transferred into a large beaker. In order to replicate the
proportions of MeOH and EtOAc present in the small scale screening, the fungal colony
was extracted first for 24 hrs in 750 mL of 1:3 MeOH:EtOAc. Following this first
extraction period, the supernatant was filtered, and the fungi was subjected to two more
24 hr extraction periods in EtOAc. After filtering the supernatant from each of these
extractions, the rice and fungal colony were discarded, and the extract was dried down
and weighed, with a small portion set aside and redissolved in DMSO for bioassay.
Chromatographic Isolation Protocol
Medium Pressure Liquid Chromatography (MPLC) was performed using a
Combiflash Rf 200i MPLC, using ELSD and UV detection with a RediSepRf 80 g silicia
column (Figure A1., Figure A3.). Normal Phase High Performance Liquid
Chromatography (HPLC) was completed with a gradient of hexanes to EtOAc over
40min on a semi-preparative Phenominex® silica column (10 μm, 100 Å, 250 x 10 mm)
using ELSD and UV detection. Reverse Phase HPLC was completed with a gradient of
H2O to either MeOH or ACN on an analytical Phenominex® C18 column (5 μm, 100 Å,
250 x 4.6 mm) using ELSD and UV detection (Figure A2., Figure A3., Figure A4.).
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Figure A1. NP MPLC Chromatogram of KLM14-75MG-C8-DNMTi. Elution gradient (percent
EtOAc, blue), UV absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace
(green), and fraction of interest are shown.

Figure A2. NP HPLC Chromatogram of KML14-75MC-C8-DNMT-E. Elution gradient (blue),
ELSD trace (black) and UV absorbance at 320 nm (yellow) are shown. Equisetin and entequisetin were isolated from the major components.
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Figure A3. NP MPLC Chromatogram of HF14-17C-3B-DNMTi. Elution gradient (percent EtOAc,
blue), UV absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace (green),
and fractions of interest are shown.

Figure A4. NP HPLC Chromatogram of HF14-17C-3B-DNMT-G5. Elution gradient (blue), ELSD
trace (black) and UV absorbance at 320 nm (yellow) are shown. Altersetin was isolated from the
major component.

Figure A5. NP HPLC chromatogram of HF14-17C-3B-DNMT-G7. Elution gradient (blue), ELSD
trace (black) and UV absorbance at 320 nm (yellow) are shown. Altertoxin I was isolated from the
major component.
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Figure A6. RP HPLC chromatogram of HF14-17C-3B-DNMT-G. Elution gradient (blue), ELSD
trace (black) and UV absorbance at 320 nm (yellow) are shown. Pyrophen was isolated from
major component, fraction 2.

Compound Data
Equisetin (1): C22H31NO4; HRESIMS m/z 356.2227 [M+H-H2O]+ (C22H30NO3, calculated
356.2225), m/z 374.2375 [M+H]+ (C22H32NO4 calculated, 374.2331), m/z 397.2251
[M+Na]+ (C22H31NO4Na calculated, 3597.2227); 1H NMR (500 MHz, CDCl3) δ ppm 0.90
(m, 1 H), 0.92 (d, 6.5, 3 H), 1.09 (q, 12.0, 1 H), 1.09 (q, 9.5, 1 H), 1.47 (br s, 3 H), 1.52
(d, 5.0, 3 H), 1.52 (m, 1 H), 1.69 (br s, 1 H), 1.75 (br m, 1 H), 1.79 (m, 1 H), 1.83 (m, 1
H), 1.97 (br m, 1 H), 3.06 (s, 3 H), 3.32 (br s, 1 H), 3.67 (br t, 5.0, 1 H), 3.9 (dd, 11.4,
6.0, 1 H), 4.07 (br d, 11.0, 1 H), 5.17 (m, 1 H), 5.25 (m, 1 H), 5.40 (br s, 1 H), 5.40 (br s,
1 H); 13C NMR (125 MHz, CDCl3) δ ppm 14.3 (CH3, C-12), 17.8 (CH3, C-15), 22.5 (CH3,
C-16), 27.2 (CH3, C-7’), 28.4 (CH2, C-10), 33.5 (CH, C-8), 35.7 (CH2, C-9), 38.6 (CH, C6), 40.0 (CH, C-11), 42.2 (CH2, C-7), 45.0 (CH, C-3), 48.8 (C-2), 60.3 (CH2, C-6’), 66.1
(CH, C-5’), 100.0 (C, C-3’), 126.6 (CH, C-4 or C-5), 127.0 (CH, C-14), 129.9 (CH, C-4 or
C-5), 130.8 (CH, C-13), 177.0, (C-2’), 190.9 (C-1), 200.2 (C-4’).
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Figure A7. 1H NMR spectrum (500 MHz, CDCl3) of equisetin (1).
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Figure A8. 13C NMR spectrum (125 MHz, CDCl3) of equisetin (1).
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Figure A9. 1H-13C gHSQC NMR spectrum (500 MHz, CDCl3) of equisetin (1).
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Figure A10. 1H-1H gCOSY NMR spectrum (500 MHz, CDCl3) of equisetin (1).
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Figure A11. H- C gHMBC NMR spectrum (500 MHz, CDCl3) of equisetin (1).
Ent-equisetin (2): C22H31NO4; HRESIMS m/z 356.2230 [M+H-H2O]+ (C22H30NO3,

calculated 356.2225), m/z 374.2370 [M+H]+ (C22H32NO4 calculated, 374.2331), m/z
397.2253 [M+Na]+ (C22H31NO4Na calculated, 3597.2227); 1H NMR (500 MHz, CDCl3) δ
ppm 0.90 (q, 12.0, 3 H), 0.92 (d, 6.5, 3 H), 1.09 (q, 12.0, 1 H), 1.04 (m, 1 H), 1.48 (br s,
1 H), 1.56 (d, 5.0, 3 H), 1.48 (m, 1 H), 1.66 (br s, 1 H), 1.77 (br m, 1 H), 1.80 (m, 1 H),
1.83 (m, 1 H), 1.96 (br m, 1 H), 3.05 (s, 3 H), 3.36 (br s, 1 H), 3.66 (br t, 3.5, 1 H), 3.85
(dd, 12.0, 3.5, 1 H), 4.05 (br d, 6.5, 1 H), 5.16 (dd, 15.0, 6.0, 1 H), 5.24 (dq, 15.0, 5.0, 1
H), 5.41 (br s, 1 H), 5.42 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 14.0 (CH3, C12), 18.2 (CH3, C-15), 22.6 (CH3, C-16), 27.0 (CH3, C-7’), 28.0 (CH2, C-10), 33.3 (CH,
C-8), 35.6 (CH2, C-9), 38.5 (CH, C-6), 42.0 (CH, C-11), 44.6 (CH2, C-7), 45.0 (CH, C-3),
48.0 (C-2), 60.0 (CH2, C-6’), 66.6 (CH, C-5’), 100.0 (C, C-3’), 126.2 (CH, C-4 or C-5),
127.1 (CH, C-14), 129.8 (CH, C-4 or C-5), 130.4 (CH, C-13), 176.8 (C-2’), 190.7 (C-1),
198.8 (C-4’).
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Figure A12. 1H NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2).

MAK6_CARBON_01.esp

0.10

0.05

0
200

180

160

140

120

100

80

60
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Figure A14. 1H- 13C gHSQC NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2).
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Figure A15. 1H- 1H gCOSY NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2).
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Figure A16.

1H- 13C

gHMBC NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2).

Altersetin (3): C24H33NO4; HRESIMS m/z 382.2374 [M+H-H2O]+ (C24H32NO3, calculated
382.2382), m/z 400.2491 [M+H]+ (C24H34NO4, calculated 400.2488), m/z 422.2304
[M+Na]+ (C24H33NO4Na, calculated 422.2307); 1H NMR (500 MHz, CDCl3) δ ppm 0.82
(m, 1 H), 0.86 (d, 7.0, 3 H), 0.99 (m, 1 H), 1.03 (m, 1 H), 1.20 (d, 6.0, 3 H), 1.35 (s, 3 H),
1.51 (m, 1 H), 1.55 (m, 1 H), 1.64 (d, 6.7, 3 H), 1.72 (m, 1 H), 1.80 (m, 1 H), 1.82 (m, 1
H), 1.89 (m, 1 H), 3.43 (m, 1 H), 3.60 (br s, 1 H), 3.90 (m, 1 H), 5.24 (dd, 14.0, 4.0, 1 H),
5.36 (m, 1 H), 5.45 (m, 1 H), 5.50 (dq, 15.2, 5.5, 1 H), 5.71 (dd, 10.9, 3.0, 1 H), 5.88 (dd,
11.0, 3.0, 1 H), 9.22 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 14.0 (CH, C-22),
18.9 (CH3, C-21), 21.2 (CH, C-24), 22.7 (CH3, C-23), 28.0 (CH2, C-9), 33.0 (CH, C-11),
36.0 (CH2, C-10) 38.0 (CH C-13), 39.1 (CH, C-8), 42.0 (CH2, C-12), 45.5 (C-7), 45.5
(CH, C-16), 66.1 (CH3, C-16), 66.9 (CH, C-5), 100.0 (C-3), 126.2 (CH, C-15), 128.5
(CH, C-20), 130.0 (CH, C-17), 131.0 (CH, C-14), 131.5 (CH, C-18), 131.5 (CH, C-19),
182.8 (C-2), 191.5 (C-4), 199.1 (C-6).
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Figure A17. 1H NMR spectrum (500 MHz, CDCl3) of altersetin (3).

Figure A18. 13C NMR spectrum (125 MHz, CDCl3) of altersetin (3).
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Figure A19. 1H- 13C gHSQC NMR spectrum (500 MHz, CDCl3) of altersetin (3).
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Figure A20. 1H- 1H gCOSY NMR spectrum (500 MHz, CDCl3) of altersetin (3).
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Figure A21. 1H- 13C gHMBC NMR spectrum (500 MHz, CDCl3) of altersetin (3).

Altertoxin I (4): C20H16O6; HRESIMS m/z 317.0811 [M+H-2H2O]+ (C20H13O4, calculated
317.0814), m/z 335.0915 [M+H-H2O]+ (C20H15O5, calculated 335.0915), m/z 353.1021
[M+H]+ (C20H17O6, calculated 353.1025); 1H NMR (600 MHz, MeOH-d4) δ ppm 2.43 (td,
14.3, 4.1, 1 H), 2.69 (dt, 16.7, 3.1, 1 H), 2.91 (dd, 16.1, 12.0, 1 H), 3.01 (m, 1 H), 3.07
(d, 5.5, 1 H), 3.08 (m, 1 H), 3.17 (m, 1 H), 4.76 (m, 1 H), 7.02 (d, 8.8, 1 H), 7.07 (d, 8.8,
1 H), 7.81 (d, 8.7, 1 H), 7.83 (d, 8.7, 1 H), 12.34 (s, 1 H), 12.69 (s, 1 H);

13C

NMR

(taken from gHMBC spectrum) δ ppm 33.9 (CH2, C-5), 34.4 (CH2, C-6), 47.7 (CH2, C-8)
51.9 (CH, C-6b), 66.1 (CH, C-7), 69.2 (C-6a), 116.1 (C-9a), 116.9 (C-3a), 117.6 (CH, C11), 120.0 (CH, C-2), 122.7 (C-12b), 124.4 (C-12a), 132.4 (CH, C-12), 132.6 (CH, C-1),
135.4 (C-12c), 139.1 (C-9b), 162.0 (C-10), 162.3 (C-3), 202.0 (C-9), 204.9 (C-4).
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Figure A25. 1H- 1H gCOSY NMR spectrum (600 MHz,
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Figure A26. 1H- 13C HMBC NMR spectrum (600 MHz,
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0

MeOH-d4) of altertoxin I (4).

Pyrophen (5): C16H17NO4; HRESIMS m/z 288.1230 [M+H]+ (C16H18NO4, calculated
288.1236), 310.1045 [M+Na]+ (C16H17NO4Na , calculated 310.1056); 1H NMR (500
MHz, CDCl3) δ ppm 1.96 (s, 3 H), 3.09 (d, 7.5, 2H), 3.75 (s, 3 H), 5.0 (q, 7.7, 1 H), 5.41
(d, 2.1, 1 H), 5.74 (d, 2.0, 1 H), 5.96 (d, 8.5 1H), 7.12 (m, 2 H), 7.12 (m, 2 H), 7.25 (m, 3
H), 7.25 (m, 3 H), 7.25 (m, 3 H); 13C NMR (taken from gHMBC spectrum) δ ppm 20.9
(CH3, C-2), 38.0 (CH2, C-β), 52.7 (CH, C-α), 55.5 (CH3, C-4’-OMe), 87.7 (CH, C-5’),
100.3 (CH, C-3’), 126.6 (CH, C-4’’), 128.7 (1H, C-3’’), 128.7 (CH, C-5’’), 129.0 (CH, C-

Normalized Intensity

6’’), 136.6 (C-1’’), 162.5 (C-2’), 162.9 (C-6’), 171.3 (C-1), 172.0 (C-4’).
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Figure A27. 1H NMR spectrum (500 MHz, CDCl3) of pyrophen (5).
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Figure A29. 1H- 13C gHSQC NMR spectrum (500 MHz, CDCl3) of pyrophen (5).
Py
COSY
g
_
n
e
h
p
ro

2

4

6

F2 Chemical Shif t (ppm) 2
Figure A30. 1H- 1H gCOSY NMR spectrum (500 MHz, CDCl3) of pyrophen (5).
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Figure A31. 1H- 13C gHMBC NMR spectrum (500 MHz, CDCl3) of pyrophen (5).
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Table A1. Biological Activity of 1-5 against Staphylococcus aureus.

Compound
Equisetin (1)
Ent-equisetin (2)
Altersetin (3)
Altertoxin I (4)
Pyrophen (5)

.
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IC50
(µM)
2.67
26.7
125.24
Inactive
696.1

APPENDIX B:
EXPERIMENTAL AND SUPPORTING DATA FOR CHAPTER THREE
LC-MS/MS Experimental Parameters
Database Construction Protocol
Chromatographic Isolation Protocol
Compound Data

LC-MSMS Experimental Parameters
LC-MS/MS Experiments were performed on an AgilentTM LC-QToF using
Electrospray Ionization (ESI). Crude extracts were dissolved and partitioned between
hexanes and 1:3 H2O:MeOH. Crude extracts and pure compounds were made to 1
mg/mL and 0.1 mg/mL, respectively, in MeOH. Standard Reverse Phase liquid
chromatography was completed with an elution gradient of H2O to ACN on a
Phemonenex® Kinetex® C-18 column (2.6 μm, 100 Å, 150x 3 mm). The instrument
experimental parameters are as indicated (Table B.1.).
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Table B.1. Acquisition Parameters for LC-MS/MS Experiments.

HiP Sampler

Pump

Injection Volume
Injection with needle
wash

10.0 μL

Flow

Yes

Solvent A

Needle Wash Mode
Needle Wash Time

Flush Port
3.0 sec

Draw Speed
Eject Speed
Draw Position
Equilibration Time

100.0 μL/min
100.0 μL/min
0.0 min
0.0 sec
5.0x Inj.
Volume

Solvent B
Pressure Limit Min
Pressure Limit
Max
Stop Time
Posttime

Sample Flush-out Factor

0.40 mL/min
H2O+0.1% Formic
acid
ACN+0.1% Formic
acid
0.00bar
600.00 bar
14.00 min
1.00 min

Time Table
Time [min]

A [%]
0.00
0.01
2.00
10.00
12.00
12.01
14.00

90.00
98.00
98.00
2.00
2.00
98.00
98.00

B [%]
10.00
2.00
2.00
98.00
98.00
2.00
2.00

Flow [mL/min]
0.40
0.40
0.40
0.40
0.40
0.40
0.40

QToF
General
Ion Source
Ion Polarity
Data Storage

Dual AJS ESI
Positive
Both

LC Stream
Stop Time
Cycle Time
Source

MS
As Pump
1.7 s

Gas Temp
Drying Gas

300 oC
8 l/min

Nebulizer

30 psig

Sheath Gas Temp
Sheath Gas Flow
Dual AJS ESI Vcap
Caillary
Nozzle Voltage
Chamber
Acquisition
Spectral Parameters

300 oC
11 l/min
4000 V
0.00 uA
500 V
0.00 UA

Plot and Centroid Data Storage Threshold
MS Abs Threshold
200
Rel. Threshold (%)
0.01
MS/MS Abs
Threshold
5
Rel. Threshold (%)
0.01

MS TOF
Fragmentor
MS TOF Skimmer
MS TOF OCT 1 RF
Vpp
TOF Collision
Energy
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140 V
65 V
750 V
0V

Table B.1. (Continued) Acquisition Parameters for LC-MS/MS Experiments.
Acquisition
Spectral Parameters
MS
MS/MS
Mass Range Min
40 m/z
Mass Range Min
Mass Range Max
1300 m/z
Mass Range Max
Acquisition Rate
1 spectra/s
Acquisition Rate
1000
Acquisition Time
ms/spectrum
Acquisition Time
Transients/spectrum
5971
Transients/spectrum
Isolation Width
Collision Energy

Auto
40 m/z
1300 m/z
5 spectra/s
200 ms/spectrum
1118
Medium (~4 m/z)
0 mV, 10 mV 40
mV

QToF
Precursor Selection
Max Precursor Per
Cycle
Abs. Threshold
Rel. Threshold (%)
Active Exclusion
Excluded after
Released after
Reference Mass
Mass Correction
Detection Windown
Min Height

Chromatogram
3
1000 counts
0.01%
Disabled
3 Spectra
0.5 min

Enable
100 ppm
1000 counts

Label
Expt Type
Polarity Effect
Offset
Y-Range

TIC
MS
Both
15
10000000

Ref.
Masses
121.0508
922.0098

Database Construction Protocol
LC-MS/MS data was processed using AgilentTM MassHunter Qualitative Analysis
B.05.00. Database was generated using AgilentTM Personal Compound and Database
Library (PCDL) software. Compounds were identified and spectra were collected and
extracted from MassHunter Qualitative Analysis and converted to compound entry files
in the PCDL according to manufacturer’s instructions. For each compound entry in the
PCDL, the compound name, high-resolution mass, and MS/MS profile was added. For
each compound, a lnchl structural code was generated using ACD/Labs 2016
ChemSketch software and was entered into the PCDL. All compounds within an extract
were analyzed with public databases, METLINTM-AMRT-PCDL and Mycotoxins-AMRT119

PCDL, and our own private database, Baker Lab Fungal Metabolite PCDL, using
MassHunter Qualitative Analysis as specified by manufacturer’s instructions.
Chromatographic Isolation Protocol
Medium Pressure Liquid Chromatography (MPLC) was performed using a
Combiflash Rf 200i MPLC, using ELSD and UV detection with a RediSepRf 80 g silicia
column (Figure B1.). Normal Phase High Performance Liquid Chromatography (HPLC)
was completed with a gradient of hexanes to EtOAc over 40 min on a semi-preparative
Phenominex® silica column (10 μm, 100 Å, 250 x 10 mm) using ELSD and UV
detection. Reverse Phase HPLC was completed with a gradient of H2O to MeOH on a
semi-preparative Phenominex® C18 column (10 μm, 100 Å, 250x 10 mm) (Figure 3.7.),
or with a gradient of H2O to either ACN or MeOH on an analytical Phenominex® C18
column (5 μm, 100 Å, 250 x 4.6 mm) using ELSD and UV detection (Figure B2.).

Figure B1. NP MPLC chromatogram of HF14-37B-1B-DNMTi. Elution gradient (percent EtOAc,
blue), UV absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace (green),
and fractions of interest are shown.
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Figure B2. RP HPLC chromatogram of HF14-37B-1B-DNMTi. Elution gradient (blue), ELSD trace
(black) and UV absorbance at 320 nm (yellow) are shown.3-methyl-4,1-benzoxazepine-2,5(1H,
3H)-dione was isolated from major component.

Compound Data
3-methyl-4,1-benzoxazepine-2,5(1H, 3H)-dione (1): C10H9NO3; HRESIMS m/z 174.0568
[M+H-H2O]+ (C10H8NO2, calculated 174.0555), m/z 192.0666 [M+H]+ (C10H10NO3,
calculated 192.0660); UV (MeOH) λmax (log ε) 230 (1.78); [𝛼]25
𝐷 = -37.0 (c 0.1, MeOH); IR
(thin film) 3250, 3000, 2940, 1730, 1700, 1590, 1550, 1250 cm -1; 1H NMR (400 MHz,
MeOH-d4) δ ppm 1.40 (d, 6.8, 3 H), 4.20 (q, 6.8, 1 H), 7.14 (m, 1 H), 7.47 (m, 1 H), 7.70
(dd, 7.7, 1.4, 1 H), 8.50 (dd, 8.0, 1.0, 1 H); 13C NMR (taken from gHMBC spectrum) δ
ppm 20.1 (CH3, C-10), 68.8 (CH, C-3), 121.5 (CH, C-9), 122.0 (C-5a), 123.5 (CH, C-7),
128.4 (CH, C-6), 132.7 (CH, C-8), 138.7 (C-9a), 172.2 (C-5), 175.7 (C-2).
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Figure B3. 1H NMR spectrum (400 MHz, MeOH-d4) of compound 1.
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Figure B4. 1H-13C gHSQC NMR spectrum (500 MHz, MeOH-d4) of compound 1.
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Figure B5. 1H-1H gCOSY NMR spectrum (500 MHz, MeOH-d4) of compound 1.
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Figure B6. 1H-13C gHMBC NMR spectrum (500 MHz, MeOH-d4) of compound 1.
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APPENDIX C:
EXPERIMENTAL AND SUPPORTING DATA FOR CHAPTER FOUR
Chromatographic Isolation Protocol
Compound Data

Chromatographic Isolation Protocol
Medium Pressure Liquid Chromatography (MPLC) was performed using a
Combiflash Rf 200i MPLC, using ELSD and UV detection with a RediSepRf 80 g silicia
column (Figure C1.). Reverse Phase HPLC was completed with a gradient of H2O to
MeOH on a semi-preparative Phenominex® C18 column (10 μm, 100 Å, 250 x 10 mm)
(Figure C2) or with a gradient of H2O to either ACN or MeOH on an analytical
Phenominex® C18 column (5 μm, 100 Å, 250 x 4.6 mm) using ELSD and UV detection
(Figure C3.).
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Figure C1. NP MPLC chromatogram of NBP13-24-6. Elution gradient (percent EtOAc, blue), UV
absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace (green), and
fractions of interest are shown.

Figure C2. RP HPLC chromatogram of NBP13-24-6. Elution gradient (blue), ELSD trace (black)
and UV absorbance at 320 nm (yellow) are shown. Friomaramide (1) was isolated from labeled
fraction.

Figure C3. . RP HPLC chromatogram of NBP13-24-6. Elution gradient (blue), ELSD trace (black)
and UV absorbance at 320 nm (yellow) are shown. Friomaramide (1) was isolated from major
component
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Compound Data
Friomaramide (1): C46H67N7O6; HRESIMS m/z 814.5243 [M+H]+ (C46H68N7O6,
calculated 814.5231), m/z 836.5051 [M+Na]+ (C46H67N7O6Na, calculated 836.5050); UV
(MeOH) λmax (log ε) 230 (2.81); [𝛼]25
𝐷 = -150 (c 0.1, MeOH); IR (thin film) 3450, 3050,
2980, 2960, 1700, 1680, 1635, 1500, 1240 cm -1; 1H NMR (800 MHz, MeOD) δ ppm 0.60
(d, 6.5, 3 H), 0.76 (d, 6.5, 3 H), 0.76 (d, 6.5, 3 H), 0.80 (d, 7.3, 3 H), 0.81 (d, 6.5, 3 H),
0.83 (d, 7.3, 3 H), 1.20 (d, 7.0, 3 H), 1.29 (m, 2 H), 1.32 (m, 2 H), 1.92 (s, 3 H), 1.98 (m,
1 H), 2.10 (m, 1 H), 2.21 (m, 1 H), 2.78 (s, 3 H), 2.86 (s, 3 H), 2.90 (m, 1 H), 2.95 (s, 3
H), 3.01 (s, 1 H), 3.05 (m, 1 H), 3.09 (s, 3 H), 5.09 (d, 11.0, 1 H), 5.14 (m, 1 H), 5.14 (t,
15.7, 1 H), 5.17 (m, 1 H), 5.34 (d, 10.9, 1 H), 6.31 (d, 8.3, 1 H), 6.59 (d, 8.2, 1 H), 7.08
(t, 7.2, 1 H), 7.15 (t, 7.2, 3 H), 7.22 (s, 1 H), 7.23 (br m, 1 H), 7.25 (br m, 2 H), 7.28 (br
m, 2 H), 7.36 (d, 7.8, 1 H), 7.60 (d, 7.8, 1 H); 13C NMR (200 MHz, MeOH-d4) δ ppm 16.8
(CH3, Ala-β), 17.1 (CH3, Ile-1-δ), 18.7 (CH3, Val-γ'), 19.0 (CH3, Ile-1-β-Me), 19.3 (CH3,
Ile-2-δ), 20.0 (CH3, Ile-2-β-Me), 20.8 (CH3, Val-γ), 24.1 (CH3, Ac –Me), 24.1 (CH2, Ile-1β), 29.4 (CH, Ile-2-γ), 29.9 (CH, Val-β), 31.8 (CH2, Ile-1-γ), 32.1 (CH3, Phe-N-Me), 32.1
(CH3, Ala-N-Me), 32.7 (CH3, Val-N-Me), 32.7 (CH3, Ile-1-N-Me), 35.0 (CH3, Ile-2-N-Me),
35.8 (CH2, Ile-2-β), 40.2 (CH2, Phe-β), 53.0 (CH, Phe-α), 53.3 (CH, Ala-α), 59.3 (CH,
Ile-1-α), 60.4 (CH, Val-α), 60.4 (CH, Ile-2-α), 109.8 (Trypt-3), 111.1 (CH, Trypt-7), 118.1
(CH, Trypt-4), 121.6 (CH, Trypt-α), 122.0 (CH, Trypt-5), 125.4 (CH, Trypt-6), 125.9
(CH, Trypt-β), 126.7 (Trypt-3a), 128.1 (CH, Trypt-2), 129.0 (CH, Phe- 3/5), 129.5 (CH,
Phe- 2/6), 130.0 (CH, Phe-4), 136.8 (Trypt-7a), 136.9 (Phe-1), 170.3 (Val-CO), 170.4
(Ile-1-CO), 170.8 (Ile-2-CO), 171.3 (Ac-CO), 172.4 (Phe-CO), 173.3 (Ala-CO).
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Figure C4. 1H NMR spectrum (800 MHz, MeOD) for friomaramide (1).
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Figure C6. 1H-13C gHSQC NMR spectrum (800 MHz, MeOH-d6) for friomaramide (1).
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Figure C7. 1H-1H gCOSY NMR spectrum (800 MHz, MeOH-d6) for friomaramide (1).
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Figure C8. 1H-13C gHMBC NMR spectrum (800 MHz, MeOH-d6) for friomaramide (1).

Marfey’s Analysis
A portion of 1 (0.3 mg) was hydrolyzed at 120 oC with 6M HCL for 24 hrs. A 0.1
M NaHCO3 solution (200 μL) was added to the dried hydrolysate of 1, as well as to Land D- amino acids standards of N-Me valine, N-Me alanine, N-Me phenylalanine, N-Me
isoleucine, N-Me allo-isoleucine. A solution of Marfey’s reagent, FDAA (Nα-(2,4-dinitro5-flourophenyl-L-alaninamide) in acetone (25 mg in 50 μL) was added to each
hydrolysate and standard, and each was incubated at 90 oC for 10 minutes. To quench
each reaction, 100 μL of 2 M HCL was added and then diluted with 300 μL of
acetonitrile. The Marfey’s derivatives of the hydrolysate and standards were analyzed
using LC-MS-ToF with a Phemonenex® Kinetex® C-18 column (2.6 μm, 100 Å, 150 x 3
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mm), with an elution gradient of 75% H2O/25% acetonitrile acidified with 0.1% formic
acid to 20% H2O/80% acetonitrile acidified with 0.1% formic acid over 10 minutes at a
0.4 mL/min flow rate. Comparison of retention time and mass of each Marfey’s
derivative of the hydrolysate and standard was used to determine the absolute
stereochemistry of 1 (Table C1.).
Table C1. Marfey’s analysis of friomaramide (1).

N-Me
Amino Acid
D-Ala
L-Ala
D-Ile
L-Ile
D-allo-Ile
L-allo-Ile
D-Phe
L-Phe
D-Val
L-Val

Retention Time
(min)
5.77
5.91
6.94
7.57
7.20
7.39
7.31
7.19
7.41
6.98
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Friomaramide Amino
Acid Retention Time
(min)
5.89
7.56

7.32

7.03

